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Too often, prescription medications once thought safe for human use cause 
unacceptable adverse health consequences and fail during clinical testing or are recalled 
after public release. One major contributing factor to this problem is the inability of 
current in vitro and in vivo toxicity assessment methods to adequately detect toxicity 
caused by pharmaceuticals during preclinical trials. We have developed a novel toxicity 
discovery and quantification method known as the organismal performance assay (OPA) 
that is capable of revealing mammalian health consequences with great sensitivity. OPAs 
utilize genetically diverse wild mice (Mus musculus) that compete amongst each other for 
limited resources in seminatural enclosures. OPAs achieve their sensitivity because they 
are unique in that no hypotheses pertaining to specific mechanisms of action are needed. 
Rather, whole organismal performance in its entirety is measured by OPAs in a 
seminatural environment. As a result, any substance or treatment that reduces 
performance of almost any physiological system is likely to be detected by OPAs as the 
endpoint measures (reproductive success, survival, and male competitive ability) of 
performance are integrated across physiological systems. In order for individuals to 
become successful in OPAs, high performance of most physiological systems is needed. 
To demonstrate OPAs sensitivity and the potential utilization during preclinical trials, we 
assessed three pharmaceuticals: two of which have already been recalled from the market 
(cerivastatin and rofecoxib) and one that is still available, but is suspected of causing 
 congenital malformations (paroxetine). First, we examined organismal performance 
consequences associated with exposure to cerivastatin and observed that exposed females 
had reduced reproduction and males had reduced weight, competitive ability, 
reproduction, and survival. Next, we tested the safety of paroxetine exposure and found 
that females had reduced reproduction but appeared to recover from fitness declines after 
prolonged periods without exposure; however, exposed males suffered lifetime 
consequences of reduced weight, competitive ability, reproduction, and survival. Then, 
we assessed the safety of rofecoxib and found that exposed females had an increase in 
reproduction but the exposure did not affect male weight, competitive ability, 
reproduction, or mortality. Lastly, as we observed that paroxetine-exposed breeders 
produced litters with a significant sex-ratio bias towards female offspring, we then 
analyzed these data in the context of both the Trivers-Willard hypothesis and the cost of 
reproduction hypothesis. We found support for the Trivers-Willard hypothesis as females 
from biased litters out-reproduced their brothers in seminatural enclosures. These data 
suggest that OPAs are more sensitive in detecting physiological adversity than other 
currently used assays and by implementing OPAs into preclinical trials, they could 
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USING ORGANISMAL PERFORMANCE ASSAYS TO 
ASSESS THE SAFETY OF PHARMACEUTICALS 
 
1.1 Abstract 
Too often, prescription medications once thought safe for human use are found to 
cause adverse health consequences and fail during clinical testing or are recalled after 
public release. One major problem is the inability of current toxicity assessment methods 
to detect many toxicities caused by pharmaceuticals during preclinical trials. Thus, there 
is a great need for a broad, sensitive, and functional assay to test the safety of 
pharmaceuticals. We have developed an alternative research method that is capable of 
revealing mammalian health consequences, known as the organismal performance assay 
(OPA). OPAs utilize genetically diverse wild mice (Mus musculus) where individuals 
from different treatments compete amongst each other for limited resources in 
seminatural enclosures. Organismal performance is measured in terms of Darwinian 
fitness (i.e., reproduction) and factors that contribute to fitness (e.g., survival and social 
dominance). OPAs are sensitive, broad, and functional because they demand high 
performance of most physiological systems simultaneously in order for individuals to be 
successful. OPAs have proven powerful in detecting adverse health effects from genetic 
inbreeding, bearing a selfish gene, and consuming added sugar at human relevant levels 
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that were all missed by conventional methodologies. The implementation of OPAs during 
preclinical trials has the potential to dramatically increase the detection rate of harmful 
substances before they move onto human testing.   
 
1.2 Background 
The drug approval process is costly and requires several years of research. From 
the time a new chemical entity (NCE) is discovered until market launch, it is estimated to 
cost more than $1.4 billion and typically takes 12-15 years of preclinical and clinical 
research (Miller 2012). Despite this large investment, 73% of pharmaceuticals that pass 
preclinical trials fail during clinical testing (Lipsky and Sharp 2001) and 10% of all Food 
and Drug Administration (FDA)-approved pharmaceuticals fail after market launch due 
to unacceptable adverse drug reactions (ADRs) (Schuster et al. 2005). These harmful 
drugs are then recalled from the market or labeled with black box warnings that warn 
consumers of the serious risks (Lipsky and Sharp 2001, Schuster et al. 2005). For 
example, troglitazone (Rezulin®, Parke Davis/Warner-Lambert) was a prescription anti-
diabetic drug, which was discovered to cause liver toxicity and was linked with 83 cases 
of liver failure. Troglitazone was on the market for three years before the FDA 
recommended the drug be recalled (Faich and Moseley 2001). However, unlike 
troglitazone, some ADRs are not discovered until several years later; for example, 
fenluaramine (Pondimin®, Wyeth-Ayerst Laboratories) and phentermine (Lonamin®, 
Wyeth-Ayerst Laboratories), or Fen-Phen, was on the market for 24 years before the link 
to valvular heart disease was discovered (Connolly et al. 1997). With 10% of 
pharmaceuticals failing after approval, it is clear that one of the biggest challenges 
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pharmaceutical companies face during the approval process is the identification of 
unpredictable harmful physiological effects.  
Preclinical trials are the initial phase of drug development and include both in 
vivo and in vitro safety testing. One of the main objectives of in vitro testing is to assess 
drug-induced toxicities by tissue culture or organ specific assays. As cardiac and liver 
toxicity are the two primary causes of drug failure, they are routinely addressed in 
preclinical trials (Schuster et al. 2005). The hERG (human EtheR-a-Go-go) channel is a 
potassium channel that is important to the electrophysiology of the heart. Several drugs 
have inadvertently inhibited the function of the hERG channel and consequently, this 
channel has been evaluated during drug development (Brimecombe et al. 2009). In vitro 
assays used to assess hepatotoxicity include the use of both cell culture and liver slices 
(Dambach et al. 2005). Liver enzyme levels such as alanine aminotransferase (ALT), 
aspartate aminotransferase (AST), and lactate dehydrogenase (LDH) are monitored and 
the induction of cytochrome P450 (CYP450) is tested for abnormal levels (Dambach et 
al. 2005, Peters 2005). These in vitro preclinical tests are sensitive and functional (i.e., 
they generate conclusive results), but they ignore the importance of synergy between 
physiological systems.  
Toxicogenomics is becoming an increasingly popular tool to identify the genetic 
basis of toxicity and to assist with safer drug development. Microarray analysis of drug 
exposure is mainly conducted using in vitro models but has been applied to some animal 
models. Microarray analyses conducted in an in vitro model has been criticized for 
ignoring the physiological interactions within an organism (Yang et al. 2004). These 
analyses are broad and sensitive, sometimes revealing thousands of differentially 
 4 
expressed genes between treated and control tissues. However, the data generated from 
such analyses are nonfunctional because they generate inconclusive data; this is because 
it remains unclear if these expression changes are beneficial, neutral, or deleterious. In 
order to determine if the differential gene expression caused by the NCE is deleterious, 
these data are compared to microarray data of known toxicants (Yang et al. 2004), but 
because the reference database is largely incomplete, the problem remains in determining 
the functional consequences of differential gene expression caused by NCEs. 
The objectives of in vivo preclinical trials are to determine if a NCE induces 
carcinogenicity, mutagenicity, reproductive toxicity, and teratogenicity (Kotsonis et al. 
1985, Lipsky and Sharp 2001). NCEs are typically required to be tested in two different 
species, one rodent model, usually rat or mouse, and one nonrodent model, usually dog 
(Peters 2005). Concordance of human toxicity predicted by rodent models is 43% while 
concordance in nonrodents are typically higher, 63%, but by testing in both classes of 
animal models, toxicity in humans can be predicted with 70% accuracy (Olson et al. 
2000). Once a “no observable adverse effect level” (NOAEL) has been established, then 
a safe dose can be established for humans and then the NCE enters clinical trials.  
 
1.3 Organismal Performance Assays (OPAs) 
Failure to detect ADRs in preclinical studies may largely be due to the lack of 
assays that have all three criteria of being broad, sensitive, and functional. We have 
developed an assay, known as the Organismal Performance Assay (OPA), that is capable 
of revealing mammalian health consequences. OPAs utilize genetically diverse wild-
derived mice (Mus musculus) where individuals from different treatments compete 
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directly with each other for limited resources in seminatural enclosures. Individual 
performance is measured in terms of Darwinian fitness (i.e., reproductive success) and 
components that lead to fitness (e.g., competitive ability and survival). OPAs are 
sensitive and broad because they challenge most physiological systems synergistically 
and in order for individuals to be successful (functional), high performance from these 
physiological systems is required (broad and sensitive). In several instances, OPAs have 
proven capable of detecting mammalian health declines with higher sensitivity than 
current in vivo and in vitro approaches. Pharmaceutical companies utilizing OPAs have 
the potential to dramatically increase the detection rate of harmful substances before 
these pharmaceutical move onto human testing.   
All OPAs consist of seminatural enclosures that are ~ 30 m2  and are divided into 
six territories by hardware mesh. These fences are easily scaled but add an element of 
spatial complexity. Each territory has free access to food and water (gallon poultry 
waterers) and contains multiple nesting sites. Within an enclosure, four of the territories 
are considered optimal. The optimal dark nest boxes consist of a large plastic storage bin 
(75 L) with one defendable 5 cm diameter entrance. Within the tubs, there are three 
standard shoebox mouse cages with nesting material and also contain a 5 cm diameter 
entrance. Optimal territories also have direct access to food, where individuals do not 
need to leave the nest box to feed. The suboptimal nest boxes consist of two light-
exposed plantar boxes with wire tops. Each plantar box has two 5 cm diameter entrance 
holes, making them difficult to defend. Individuals inhabiting the suboptimal territories 
have to leave the nesting sites to feed at the adjacent feeding station. Collectively, the 
fences and different nesting sites created environmental complexity that wild mice used 
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to establish territories and social hierarchy. Unlike animals housed in cages (like those 
used in preclinical studies), mice competing in these stressful seminatural enclosures 
require high performance from most of their physiological systems to establish social 
dominance and become successful individuals.  
 
1.4 Validation of OPAs 
OPAs have previously been used to quantify fitness costs associated with several 
different types of treatments, including genetic inbreeding. Inbreeding depression causes 
health consequences by increasing the likelihood of expressing deleterious recessive 
alleles that are otherwise masked in heterozygous outbred animals (Meagher et al. 2000). 
Previous lab based experiments revealed a 10% reduction in litter size when parents were 
full siblings (Lynch 1977, Connor and Belucci 1979). However, these experiments were 
conducted on animals within a caged environment and therefore lacked natural stressors 
such as competition for mates and resources. OPAs were used to assess fitness 
degradations in inbred offspring resulting from full-sibling crosses. Inbred progeny were 
released into seminatural enclosures where they competed directly with outbred 
individuals. OPAs quantified health degradations of full-sibling inbred progeny and male 
offspring were found to have a 500% fitness decline when they were in direct 
competition with outbred males (Meagher et al. 2000). OPAs were then used to examine 
the fitness costs associated with a single generation of cousin-level inbreeding and was 
found to cause a 34% fitness in reduction (Ilmonen et al. 2008), an adverse effect that 
remained undetected in previous studies. 
 7 
In addition to examining the negative effects associated with genetic inbreeding, 
OPAs have also been used to identify and quantify the deleterious effects of a selfish 
gene. The t complex has become a classic example of a selfish gene ever since its 
discovery nearly half a century ago. The t complex sabotages wild-type gametes and is 
inherited at a frequency of ~90%; however, in wild mouse populations, the t complex is 
detected at levels far below the expected rate (Lewontin 1968). Consequently, it was 
predicted that some form of selection has prevented the t haplotype from going to fixation 
within wild mouse populations. OPAs were used to evaluate this phenomenon where wild 
type individuals (+/+ homozygotes) were in direct competition with heterozygotes (+/t) 
and t/t homozygotes (t/t causes male sterility or embryonic mortality). OPAs revealed a 
strong selection against t bearing heterozygotes in both males and females. Heterozygous 
males were less dominant than wild type males and because females prefer to mate with 
dominant males at a higher frequency, this selection lead to the t complex being inherited 
at a rate ~49% less than what was expected in the wild (Carroll et al. 2004).  
Most recently, OPAs have been used to quantify the impacts of added sugar at 
human relevant levels. Added sugar consumption has been correlated with a number of 
diseases such as obesity, type-2 diabetes, metabolic syndrome, hypertension, and fatty 
liver disease (Bray et al. 2004, Gross et al. 2004, Dhingra et al. 2007, Ouyang et al. 2008, 
Fung et al. 2009) In the early 1970s, high fructose corn syrup (HFCS) became 
progressively incorporated into processed foods such as soft drinks and desserts and by 
1985, HFCS accounted for approximately 35-40% of sweeteners in food (Elliott et al. 
2002, Bray et al. 2004). Two OPA experiments were used to assess fitness impacts of 
added sweeteners at human relevant levels. The first experiment addressed whether 
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fitness was impacted when exposed to 25% Kcals coming from HFCS when compared 
with starch-fed individuals. HFCS-fed females experienced a twofold increased in 
mortality while males occupied ~25% fewer territories and had ~25% fewer offspring 
(Ruff et al. 2013). The second experiment compared the health effects between two types 
of added sugar, HFCS and sucrose (table sugar). In this experiment, HFCS fed females 
experienced approximately a twofold increase in mortality and experienced reduced 
reproduction of ~25% when compared to sucrose-fed females (Ruff et al. in review). In 
all of these studies (genetic inbreeding, selfish gene, and added sugar), OPAs found 
substantial deleterious effects that were missed by current methodologies.   
The following chapters represent the first application of OPAs to detect and 
quantify fitness impacts associated with pharmaceutical drug exposure. We chose three 
pharmaceuticals that have already been recalled after market release (Vioxx® and 
Baycol®) or that remain on the market with warnings, while adverse effects are 
controversial (Paxil®). By testing pharmaceuticals that are already known to cause or 
suspected of causing adverse health consequences, we can validate OPAs as a sensitive 
technique and suggest they be implemented during preclinical trials.  
 
1.5 Chapter Summaries 
 In Chapter 2, OPAs were used to evaluate the safety of cerivastatin (Baycol®, 
Bayer), a pharmaceutical belonging to the statin drug class, which aim to lower low-
density lipoprotein (HDL) cholesterol. Cerivastatin was recalled three years after market 
release due to unacceptable adverse health consequences (Wooltorton 2001). During 
preclinical assessments, cerivastatin was deemed safe after it was found to have a similar 
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toxicological profile of other statins (Keutz and Schluter 1998). Despite the large 
investment of resources into preclinical and clinical trials, cerivastatin was found to cause 
rhabdomyolysis (breakdown of skeletal muscle causing kidney toxicity) at a rate of 16-80 
times greater than other statins and was responsible for > 50 human fatalities (Furberg 
and Pitt 2001, Pasternak et al. 2002). Cerivastatin safety was assessed by OPAs and 
revealed numerous health consequences associated with previous exposure (from in utero 
into early adulthood) at a dose 27 times human therapeutic dose, but still within range of 
preclinical studies (Keutz and Schluter 1998). Within OPAs, cerivastatin-exposed males 
experienced threefold increase in mortality, sired 41% fewer offspring, and occupied 
63% fewer territories when compared with controls. Cerivastatin-exposed females also 
experienced reduced reproduction where they had 25% fewer offspring than control 
females. These fitness declines escaped the detection of current preclinical methodologies 
and thus suggest that fitness assays like OPAs could be a powerful tool for safety testing 
during pharmaceutical development. 
In Chapter 3, OPAs were used to assess the safety paroxetine (Paxil®, 
GlaxoSmithKline), a pharmaceutical currently available on the market. Paroxetine 
belongs to the selective serotonin reuptake inhibitors (SSRIs) drug class that are 
prescribed to treat cases of depression, anxiety, and other mood disorders. Paroxetine was 
approved for market use in the early 1990s and was later suspected of causing congenital 
malformations in babies born to mothers who took the drug during pregnancy; however, 
many studies are still controversial (Kulin et al. 1998, Williams and Wooltorton 2005, 
Bérard et al. 2007, Källén and Otterblad Olausson 2007, Diav-Citrin et al. 2008, Ellfolk 
and Malm 2010). In 2005, the FDA requested that paroxetine be labeled as a class D drug 
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(positive evidence of human fetal risk) and issued a warning that paroxetine exposure in 
the first trimester may potentially cause birth defects (FDA 2005). During typical 
preclinical trials, with doses 2.5-8-fold higher than human therapeutic dose, paroxetine 
caused infertility in rats but was not found to be teratogenic. In our experiment, exposure 
of paroxetine was administered near human therapeutic doses via food and occurred in 
utero and continued until early adulthood. Exposure ceased when animals were released 
into OPAs, thus any adverse health consequences detected would have been from 
previous exposure. OPAs revealed that paroxetine exposure decreased male reproductive 
success by 44%, decreased male competitive ability by 53%, and increased mortality by 
2.5-fold. Paroxetine-exposed females had reduced reproduction of 65% at the initial OPA 
time point but rebound at later time points, suggesting that the negative effects of the 
drug wore off in females. These data indicate that OPAs provide superior sensitivity 
compared to conventional approaches and indicate OPAs could be a useful tool in safety 
testing during pharmaceutical development.  
In Chapter 4, we evaluated a particularly interesting result we detected in the 
previously described experiment regarding paroxetine exposure. Litters from paroxetine 
breeders were significantly biased towards female offspring while litter size was 
unaffected when compared to control breeders. Sex allocation theory suggests that 
parents that facultatively adjust their sex ratio and/or invest more resources into one sex 
over the other can increase their lifetime reproductive success. Trivers and Willard 
(1973) suggest that in polygynous mating systems, high-quality mothers will produce 
high-quality sons, who will outreproduce their sisters of the same condition, while the 
opposite is true. The cost of reproduction hypothesis suggests that differential resource 
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investment will increase the prospect that one sex will survive and reproduce (Cockburn 
et al. 2002); both of these ideas are centralized around increasing individual lifetime 
fitness by favoring the sex of the offspring that has the highest prospect of surviving and 
passing on genetic material into future generations. In this experiment, we examined 
whether paroxetine-exposed mothers saved energy (in terms of offspring wean weight) 
by producing fewer sons. We then experimentally tested whether female offspring from 
female biased litters out reproduced the males from the same litter, when competing 
directly against individuals from unbiased (control) litters under seminatural conditions. 
Male offspring born to control mothers (unbiased litters) weighed significantly more than 
female offspring; however, no differences in wean weights were detected between male 
and female offspring from paroxetine-exposed mothers (biased litters). This suggests that 
paroxetine-exposed mothers did not save energy by skewing their litters towards female 
offspring because males did not cost more to raise than females. When offspring were in 
seminatural enclosures, we found that female offspring from paroxetine-exposed mothers 
had significantly more offspring compared to their brothers relative to controls. These 
data suggest that paroxetine-exposed mothers were successful at increasing their lifetime 
reproductive success by skewing litters towards females and is the first experimental 
evidence of determining the reproductive success of progeny from biased litters that 
provides support for the Trivers-Willard hypothesis. 
In Chapter 5, OPAs were used to assess the safety of rofecoxib (Vioxx®, Merck), 
a selective nonsteroidal anti-inflammatory drug (NSAID). Rofecoxib was on the market 
from 1999 until 2004 and was recalled after being linked with causing heart attacks in 
27,000 patients who took the drug. The deleterious effects associated with rofecoxib 
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escaped the detection of OPAs. No differences were detected in male fitness, where 
control and rofecoxib-exposed males had equal reproductive success, survival, and 
competitive ability. Rofecoxib exposed females, however, had 40% more offspring than 
control females. This is only the second study to which OPAs failed to detect adversity, 
and therefore, OPAs would still be useful if implemented drug development.  
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CHAPTER 2  
 
CERIVASTATIN EXPOSURE DECREASES FITNESS, SURVIVAL, AND 




We utilized a novel toxicity assessment method known as the organismal 
performance assay (OPA) to evaluate the safety of cerivastatin, a drug withdrawn from 
the market due to numerous unforeseen toxicities and human fatalities. OPAs evaluate 
individual performance by utilizing genetically diverse wild mice (Mus musculus) that 
are assigned to treatment and control groups that compete amongst each other for limited 
resources in seminatural enclosures. Performance measures included reproductive 
success, survivorship, and male territorial acquisition. Within OPAs, cerivastatin-exposed 
females had 25% fewer offspring when compared with controls. Cerivastatin-exposed 
males weighed 10% less, occupied 63% fewer territories, sired 41% fewer offspring, and 
experienced a threefold increase in mortality when compared to controls. OPAs detected 
several fitness declines induced by cerivastatin, which were not detected with current 
preclinical toxicology assessments, indicating that fitness assays like OPAs could be a 




Statins belong to a well-known drug class that are prescribed to patients to reduce 
low-density lipoprotein (LDL) cholesterol (Sirvent et al., 2008). In 1998, cerivastatin 
(Baycol®, Lipobay®; Bayer, Leverkusen, Germany) was approved for market use, but 
was recalled in 2001 due to unacceptable health consequences (Wooltorton, 2001). 
Specifically, cerivastatin was linked to 385 nonfatal and 52 fatal cases of rhabdomyolysis 
(the breakdown of skeletal muscle leading to kidney toxicity) in the 700,000 patients 
taking the drug (Furberg and Pitt, 2001). Forty percent of fatalities were linked to a drug-
drug interaction with gemfibrozil (Lopid; Pfizer). However, when taken alone, 
cerivastatin was still 16 to 80 times more likely to cause rhabdomyolysis than other 
statins when prescribed at the highest therapeutic dose of 0.8 mg per day (Furberg and 
Pitt, 2001; Pasternak et al., 2002).  
Preclinical studies were conducted in several animal models to assess the effects 
of cerivastatin on teratogenicity, mutagenicity, carcinogenicity, and fertility (Keutz and 
Schluter, 1998). Adverse effects on the liver and muscle tissue were detected in rodent 
models, but cerivastatin was not teratogenic, mutagenic, nor did it cause infertility (Keutz 
and Schluter, 1998). Preclinical trials suggested cerivastatin to have a similar 
toxicological profile to that of other statins whose adverse effects were primarily in 
muscle tissue and the liver (Keutz and Schluter, 1998). These studies deemed cerivastatin 
safe, which supported moving cerivastatin into human clinical trials.  
 The case of cerivastatin is not unique because over the course of drug 
development, 73% of pharmaceuticals that pass the preclinical phase of testing fail during 
clinical trials (Lipsky and Sharp, 2001) and furthermore, 10% of all Food and Drug 
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Administration (FDA) approved pharmaceuticals fail after market release due to 
unforeseen adversity (Schuster et al., 2005). Not only is drug development fraught with 
risk, but it requires between 12-15 years of research and also typically costs companies 
$1.4 billion per drug (Miller, 2012). In addition to human cost in pain, suffering, and loss 
of life, drugs that fail after market release can cause pharmaceutical companies 
substantial losses due to litigation fees; for example, Bayer’s settlement for cerivastatin 
was approximately $1.2 billion (Campbell et al., 2010). One potential cause of numerous 
drugs failing after years of research is the inability of current preclinical methodologies to 
detect adverse drug reactions (ADRs) without ambiguous interpretation; many toxicity 
assessment methods detect differences in parameters, but provide little information on 
whether observed changes are biologically adverse, beneficial, or neutral.  
 We have developed a novel toxicity assay, known as the organismal performance 
assay (OPA), which provides an unrivaled combination of breadth, sensitivity, and 
unambiguous adversity information, which will make it valuable during preclinical 
testing. OPAs utilize genetically diverse wild-derived mice (Mus musculus) that compete 
amongst each other for limited resources, such as food and mates, in a seminatural 
environment. Treatment and control individuals compete directly and the performance of 
individuals is measured in terms of Darwinian fitness (i.e., reproductive success) and the 
components that influence fitness (i.e., survival and male competitive ability). The 
sensitivity of the OPA derives from the fact that wild mice under social competition 
allows small changes in behavior or physiological performance and otherwise cryptic 
effects of toxicity to be manifested as measureable negative outcomes, such as relegation 
to inferior habitat and reduced reproduction and survival. Consequently, any degradation 
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in health caused by a treatment will be detectable by the inability of mice to perform 
comparable to controls with whom they compete. OPAs have been used to quantify the 
adverse effects of a broad array of treatments, including both genetic and nutritional 
manipulations (Meagher et al., 2000, Carroll et al., 2004, Ilmonen et al., 2008, Ruff et 
al., 2013); in all of these studies, OPAs found substantial deleterious effects that were 
missed by available in vitro and in vivo approaches.  
Here we use OPAs to determine if cerivastatin exposure causes health and fitness 
declines in mice. Our findings will address the current lack of information concerning 
consequences of cerivastatin exposure at an organismal level. If cerivastatin exposure 
adversely affects any physiological system, we predict that exposed individuals will 
suffer survival and reproduction declines and males will be less dominant relative to 
controls. If OPAs are successful in detecting cerivastatin-induced adversity, these results 
will provide evidence that OPAs would be powerful tool if implemented during 
preclinical studies, where previous preclinical methodologies deemed cerivastatin to be 
safe. 
 
2.3 Materials and Methods  
2.3.1 Animals. Genetically diverse, wild-derived house mice were used in this 
experiment as they have retained behavioral traits that allow them to function 
successfully in seminatural environments unlike mice from inbred lines (Nelson et al., 
2013). Individuals used in this experiment were from the 12th generation of the colony 
initially described in Meagher et al., (2000). Consanguinity was assessed during the 11th 
generation and found to be comparable to wild populations (Cunningham et al., 2013). 
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Animals were kept on a 12:12 h light:dark cycle and provided with food and water ad 
libitum. All procedures and protocols were approved by IACUC at the University of 
Utah. 
2.3.2 Cerivastatin exposure. Dosing was achieved by incorporating 1.5 g of 
cerivastatin (Sequoia Research Products, Pangbourne, United Kingdom; Molecular 
formula: C26H33FNNaO5) into 50 kg of standard rodent chow (TD.130006; Harlan 
Teklad, Madison, WI). As wild mice eat ~3 g per day, individuals received ~0.09 mg of 
cerivastatin daily, or ~4.5 mg/kg/day, assuming the average mouse weighs 20 g (Reagan-
Shaw et al., 2008). Using a metabolic rate conversion factor, this is equivalent to a 
human dose of ~0.36 mg/kg/day, or a daily dose of ~21.6 mg, assuming the average 
human weighs 60 kg (Reagan-Shaw et al., 2008). Cerivastatin was prescribed up to a 
daily dose of 0.8 mg (Furberg and Pitt, 2001). Our mouse dose was approximately 27 
times higher than human therapeutic doses, but still within the range of preclinical testing 
(Keutz and Schluter, 1998).  
Forty breeding pairs were randomly and equally assigned to either cerivastatin or 
control treatments. Females and males were kept separate for one week prior to breeding. 
Cerivastatin females were exposed seven days prior to pairing and males were exposed 
six days prior. Breeders were kept together until they produced a maximum of three 
litters. At 28 days, pups were weaned and separated into same sex sibling cages. Data 
collected during weaning consisted of litter size, pup weights, and sex. Exposure 
continued until pups became adults and were released into enclosures. This duration of 
cerivastatin exposure maximized the ability of OPAs to detect health consequences 
because once animals were released into the seminatural enclosures, they were all fed the 
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control diet as currently, we are unable to keep animals on their respective diets while 
they are free ranging during OPAs. While control animals could have been switched to 
the cerivastatin treatment, switching the cerivastatin-exposed animals to the control diet 
was the most conservative approach of detecting fitness declines, as any differential 
fitness represented as accumulated damage due to the diet, not the current health 
degradation. 
2.3.3 OPA enclosures. Enclosures have been extensively described in Ruff et al., 
(2013). Briefly, enclosures were ~30 m2 and contained four optimal and two suboptimal 
territories (Figure S1). Optimal territories contained dark nesting sites, whereas 
suboptimal nesting sites were exposed to light. Boundaries between territories were 
established with wire mesh fencing that was easily climbed, but provided spatial 
complexity. Each territory contained access to food and water and a 12:12 h light:dark 
cycle was maintained.  
Five independent OPA populations were established, each consisting of eight 
males and 12-16 females for a total of 116 (40 males, 76 females) individuals that are 
referred to as population founders. The space and animal density is consistent with the 
range of observations from the wild (Sage, 1981). Half of the individuals of each sex 
were exposed to cerivastatin while the remaining half were from the control treatment. 
Males were on average 15.9 ± 3.9 (M±SD) weeks old and females were 16.7 ± 4.3 weeks 
old at the time of enclosure release. To prevent incidental breeding before territories were 
established, males were released into the enclosures with nonexperimental females. After 
one week, when territories were established, nonexperimental females were removed and 
replaced with experimental females. Male founders were unrelated at the cousin level or 
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above and each population consisted of one to three pairs of sisters, but the relatedness 
between females was balanced between treatments. Populations were maintained for 28 
weeks.  
2.3.4 Male competitive ability. One week prior to release, all animals received a 
passive integrated transponder (PIT) tag (TX1400ST, BioMark, Boise, ID) for 
identification purposes. PIT tag antennas were placed on top of feeding stations within 
each of the six territories in an enclosure and data from PIT tag readers (FS2001F-ISO, 
BioMark, Boise, ID) were continuously downloaded to a computer containing data-
logging software (Minimon, Culver City, CA). Two sets of PIT tag readers and antenna 
were used to collect data on OPA populations and were rotated twice weekly among 
contemporaneous populations. A male was assigned as a territorial occupant when he 
triggered > 80% of all male PIT tag readings in a particular territory over a multiday 
reading frame. PIT tag data were collected on females, but were not analyzed due to the 
lack of knowledge concerning female dominance behavior.  
2.3.5 Reproductive success. To identify reproductive success, offspring were 
removed every five weeks, sacrificed, and had a tissue sample collected for genetic 
analysis. These “pup sweeps” prevented the young from reaching sexual maturity, 
breeding with the founders, and confounding the reproductive data. The first pup sweep 
occurred at week eight; the oldest offspring during this sweep were five weeks old as the 
gestation period is three weeks. A total of 1,668 samples were collected with an average 
of 333.6 ± 105.3 (M ± SD) offspring per population. 
 In four of the five populations, reproductive success was determined on a 
population-level by examining sex-specific allelic variants described in Meagher et al., 
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(2000). Briefly, in each population, founding individuals of each treatment were selected 
based on nonoverlapping allelic variants on the Y-chromosome for males and on the 
mitochondrial genome for females. To control for confounding effects, such as 
segregating genes linked with the markers, marker assignment was balanced across 
treatments among populations. Mitochondrial genotypes were assessed in 1,280 samples 
(four of five populations) and obtained for 100% of offspring. Y-chromosome genotypes 
were assessed in all populations to determine reproductive output of males. Of the 1,668 
offspring, 818 Y- chromosome genotypes were obtained, suggesting that 98% of all 
males were typed if the sex ratio was 1:1; successfully genotyping nearly all of the 
progeny allowed for a thorough analysis of founder reproductive success.   
 Female reproductive success was determined by parentage analysis using multiple 
microsatellite loci in the one population not typed with the above method to gain more 
knowledge on individual founder reproductive success for another study. These data were 
converted to population level readouts (i.e., number of pups per treatment rather than 
number of pups per individual) and combined with the mitochondrial data for analysis. 
Between 5 and 11 autosomal microsatellite loci were amplified, scored, and analyzed in a 
stepwise fashion. Loci used were: d1mit449, d3mit22, d3mit312, d3mit333, d5mit139 
d6mit138, d9mit251, d12mit277, d14mit128, d17mit62, and d19mit110. Primer 
sequences were obtained from the Mouse Genome Informatics website, The Jackson 
Laboratory, Bar Harbor Maine (http://www.informatics.jax.org/ accessed March 2014). 
Primers were fluorescently tagged with either CY-5 or CY-3 dye. PCR products were run 
on a 14” x 17”, 6.25% denaturing acrylamide gel at 40 W for three to seven hours (locus 
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dependent). Gels containing tagged DNA fragments were imaged on a Typhoon Scanner 
8600 with ImageQuant software (Amersham Biosciences, Piscataway, NJ).  
Parentage was assigned by using Cervus 3.0 (Kalinowski et al., 2007). Allele 
frequencies were calculated using the genotypes of all candidate mothers and fathers and 
all offspring within the population. Simulations were run at 10,000 cycles with an error 
rate of 1%. Assigned parents were accepted when the trio confidence of mother, father, 
and offspring was 95%. With this rule, 97% offspring (375 of 388) were assigned to 
parent pairs.  
2.3.6 Survivorship. Survivorship was assessed by daily noninvasive health checks 
and by extensive checks during pup sweeps. These extensive checks were conducted 
every five weeks as to not disrupt territoriality formation that increases infanticidal 
behavior. Research personnel only entered the pens to rotate PIT-tag readers, fill feeders, 
freshen waterers, and conduct pup sweeps. Dead founders were removed and identified 
by PIT tags. The date of death was estimated based upon the condition of the corpse. 
Animals that were dead long before discovery were given a death date half way in 
between the last PIT tag read and the date the individual was found.  
2.3.7 Statistical analyses. Linear mixed models (LMMs) were used to analyze 
wean weight and body weight in OPAs as these data are continuous and normally 
distributed; therefore, t-values were calculated to inform p-values in conjunction with 
degrees of freedom. Generalized linear mixed models (GLMMs) were used to analyze 
litter size, reproductive success, and male competitive ability as these data are discrete 
counts and conform to either a Poisson distribution (litter size and reproductive success) 
or binomial distribution (male competitive ability); therefore, z-scores (the number of 
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standard deviations apart two population means are) were calculated to inform p-values. 
To use a GLMM with a Poisson distribution, data are logarithmically transformed, thus 
standard errors (SE) are asymmetric as values reported in the results section have been 
back-transformed. Both LMMs and GLMMs were conducted in R 3.0.2 using the lme4 
library (Bates et al., 2014, R Development Core Team, 2013). P-values were calculated 
for LMMs with the Swatterthwaite approximation under the lmerTest function 
(Kuznetsova et al., 2013). Cox proportional hazard models (PH) were used for 
survivorship; therefore, χ2 were calculated to inform p-values in conjunction with degrees 
of freedom (JMP 9.0.3, SAS institute Inc., Cary NC). A complete description of 
statistical analyses can be found in the supplementary information. 
 
2.4 Results 
2.4.1 Breeding cage measurements. No difference was detected in wean weight of 
cerivastatin-exposed first litters (model intercept) when compared with controls (LMM; n 
= 27, female offspring, t = 0.68, p = 0.51; n = 29, male offspring, t = 0.71, p = 0.48). 
Cerivastatin-exposed females weighed an average of 11.18 ± 0.55 g (M ± SE) and 
controls weighed 10.81 ± 0.35 g. Cerivastatin-exposed males weighed an average of 
12.36 ± 0.53 g and controls weighed an average of 11.98 ± 0.34 g. No effect of time 
(LMM; female, t = 1.30, p = 0.22; male, t = 1.67, p = 0.11) or time by treatment occurred 
(LMM; female, t = −0.81, p = 0.43; male, t = −0.56, p = 0.58). For a complete readout of 
mixed model results for breeding cage data (litter size and wean weight), see Table S2.1. 
Litter size was not affected by treatment in first litters (model intercept of 
GLMM; n = 30, z = −0.04, p = 0.97). Cerivastatin-exposed breeders produced 3.51 (SE 
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+0.83, −0.67) pups. Reported SEs are asymmetric as they were back-transformed from 
logarithmic data (see statistical analyses). Control breeders produced 3.49 (+0.50, −0.44) 
pups in their first litter. No effect of time (GLMM; z = 0.10, p = 0.92) or time by 
treatment occurred (GLMM; z = 1.00, p = 0.32).  
2.4.2 OPA measurements. Cerivastatin exposure affected body weight of founders 
within OPAs. A marginally significant trend was detected in which cerivastatin-exposed 
females weighed 5% less than control females at week zero (model intercept of LMM; n 
= 76, t = −1.74, p = 0.09; Figure 2.1A). Cerivastatin-exposed females weighed an average 
of 18.69 ± 0.69 (M ± SE), whereas control females weighed on average 19.89 ± 0.78 g. 
Females from both treatments gained weight over time, presumably due to pregnancy 
(LMM; t = 10.14, p < 0.0001), but no interaction between time and treatment was 
detected (LMM; t = 0.22, p = 0.83), suggesting that the trend in reduced weight 
experienced by cerivastatin-exposed females at the intercept continued throughout the 
study. For a complete readout of mixed model results for OPA weight measures data, see 
Table S2.2. 
Cerivastatin-exposed males weighed 10% less than controls at week zero (model 
intercept of LMM; n = 40, t = −3.66, p < 0.0001; Figure 2.1B). Cerivastatin-exposed 
males weighed on average 19.30 ± 0.56 g (M ± SE), while control males weighed on 
average 21.35 ± 0.56 g. Males gained weight over time (LMM; t = 9.53, p < 0.0001); 
however, no time by diet interaction was detected (LMM; t = 1.05, p = 0.30), suggesting 
that cerivastatin-exposed males weighed less than controls throughout the study.  
Male competitive ability was negatively affected by cerivastatin exposure. 
Control males were 2.5 times more likely to occupy a territory than cerivastatin-exposed 
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males at week three (model intercept). Control males occupied 49% of the territories, 
while cerivastatin-exposed males only occupied 18% territories, leaving 32% territories 
undefended (GLMM; n = 5, z = −4.55, p < 0.0001; Figure 2.2). The percent of 
undefended territories is not unusual because 2/6 (or 33%) of the territories are 
suboptimal and are often difficult to defend. No effect of time (GLMM; z = 0.99, p = 
0.32) or time by treatment were observed (GLMM; z = −1.12, p = 0.26), indicating that 
cerivastatin-exposed males acquired fewer territories over the duration of the study. For a 
complete readout of mixed model results for OPA competitive ability, see Table S2.3. 
Cerivastatin females experienced a 25% reduction in reproductive success when 
compared with controls (GLMM; n = 5, z = −3.70, p < 0.001; Figure 2.3A). Cerivastatin-
exposed females had an average of 21.82 (SE +2.09, −1.91) offspring per population, 
while controls had an average of 30.63 (+5.40, −4.58) per population at week eight 
(model intercept). Females from both treatments had more offspring over time (GLMM; 
z = 3.39, p < 0.001), but no time by treatment effect was detected (GLMM; z = 0.89, p = 
0.38), suggesting the reproductive deficiency of cerivastatin-exposed females at the 
intercept was consistent across the study. For a complete readout of mixed model results 
for OPA reproduction, see Table S2.4. 
Cerivastatin exposure also negatively affected male reproductive success where 
cerivastatin-exposed males had 41% fewer male offspring than control males (GLMM; n 
= 5, z = −4.37, p < 0.0001; Figure 2.3B). Cerivastatin-exposed males sired an average of 
9.14 (SE +1.31, −1.15) offspring per population, while controls sired an average of 16.42 
(+3.29, −2.76) offspring per population at week eight (model intercept). Males from both 
treatments had more offspring over time (GLMM; z = 2.58, p < 0.01), but no effect of 
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time by treatment was detected (GLMM; z = 0.49, p = 0.62), suggesting that the 
reproductive deficiency experienced by cerivastatin-exposed males was consistent 
throughout the study.  
Cerivastatin-exposed individuals experienced higher mortality than controls. 
Cerivastatin-exposed females had increased mortality (n = 76); however, the data were 
not analyzed due to overall low mortality; only three cerivastatin females died while 
100% of control females survived (Figure 2.4A). Cerivastatin-exposed males experienced 
a mortality rate 3.0 times that of controls (PH; n = 40, χ2 = 4.79, p = 0.03; Figure 2.4B). 
Mortality rate did not differ in replicate populations (PH; χ 2 = 1.65, p = 0.80).  
 
2.5 Discussion 
Cerivastatin-exposed individuals suffered health and fitness declines when 
compared with controls. Cerivastatin-exposed males weighed 10% less, occupied 63% 
fewer territories, sired 41% less offspring, and had a threefold increase in mortality 
compared to controls. Cerivastatin-exposed females experienced 5% trend in reduced 
weight and had significantly fewer (25%) offspring when compared with controls. All of 
these negative effects had been missed by previous preclinical testing, suggesting that 
OPAs detected important organismal health declines and if OPAs had been in use during 
preclinical testing, they could have prompted additional studies that might have prevented 
this drug from moving to clinical trials and the marketplace.  
Cerivastatin-exposed males experienced a reduction in weight in OPAs, which 
may be attributable to muscle toxicity and degeneration. Statins in general are known to 
cause myotoxicity, but typically occur at a low rate while only 1-7% of patients taking 
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statins experience this side effect (Sirvent et al., 2008). Additional research has revealed 
that exercise can exacerbate statin-induced myotoxicity (Sinzinger and O'Grady, 2004). 
Seachrist and others (2004) assessed the effect of exercise on muscle weight in 
cerivastatin-exposed rats. They found that both quadriceps and psoas muscles weighed 
significantly less in the exercised cohort (Seachrist et al., 2005). Unlike a caged 
environment, mice inhabiting OPAs engage in regular physical activity and males 
compete with each other to obtain and defend territories. It is possible that the increase in 
physical activity caused myotoxicity in cerivastatin-exposed male mice. Less severe 
weight differences were detected in female mice and may be due to less physical activity, 
while devoting more energy into reproductive efforts (Gittleman and Thompson, 1988).  
Cerivastatin-exposed males were less competitive and dominated fewer territories 
than their control counterparts. This result might be due to decreased body weight as 
males engage in physical competitions to obtain and defend territories. Larger body size 
has been shown to be beneficial in territorial acquisition and defense in mice [e.g., (van 
Zegeren, 1980; Krackow, 1993)]. Alternatively, the cerivastatin-exposed males may have 
experienced muscle fatigue that hindered their endurance, leading to decreased 
competitive ability. A third possibility is that cerivastatin-exposed males might have 
experienced decreased testosterone levels. Testosterone plays a large role in male 
behavior, especially competitive behaviors in mice (Zielinski and Vandenbergh, 1993). 
The synthesis of testosterone and other steroid hormones relies upon available cholesterol 
(Bohm et al., 2004), which cerivastatin reduces. Some epidemiological evidence exists to 
suggest statin use does indeed lower testosterone levels ( Hyyppä et al., 2003; Corona et 
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al., 2010); however, other studies have not found an association (Bohm et al., 2004; Hall 
et al., 2007) and thus, this issue is still controversial.   
 Cerivastatin-exposed males suffered reproductive declines when compared with 
controls. In a previous OPA study, dominant males were found to sire > 80% of offspring 
born in enclosures (Carroll et al., 2004); therefore, the differences detected in competitive 
ability are likely to explain, at least in part, the differences detected in reproduction. As 
cerivastatin-exposed males experienced a threefold increase in mortality, fewer males 
were reproducing and contributing to overall population-level reproduction. It is likely 
that other mechanisms contribute to reduced reproduction. For example, one study found 
that when male rats were exposed to atorvastatin (Lipitor®, Pfizer), at levels equivalent 
to 16 times human therapeutic dose, they had decreased sperm motility and spermatid 
head concentrations and increased sperm abnormalities (Pfizer, 2009), but cerivastatin 
induced reproductive impairments have not been detected in previous rodent studies 
(Keutz and Schluter, 1998).  
 Cerivastatin-exposed females had 25% fewer offspring in OPAs when compared 
to control females. The proximate mechanisms of reduced reproductive success are 
unknown; however, it is possible that reduced cholesterol levels caused by cerivastatin 
exposure may have contributed to these findings. Cholesterol is important for normal 
fetal development (Belknap and Dietschy, 1988) and is the precursor for several 
hormones, which play important roles in pregnancy and lactation (Henck et al., 1998; 
Bohm et al., 2004). Furthermore, statins inhibit the synthesis of isoprenoids, which are 
important for maintaining cell function and normal development (Surani et al., 1983). 
Another possibility is that cerivastatin might have unknown side effects on reproduction 
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that are not associated with reduced cholesterol levels. Even though the proximate 
mechanisms are not fully understood, OPAs detected important organismal health 
declines, which is ultimately the most critical information acquired during 
pharmaceutical safety assessment.   
Although fitness declines were detected in both sexes, cerivastatin-exposed males 
suffered greater adversity than did females. This is not the first OPA study to detect 
differential health consequences between sexes. In three previous OPA studies, males 
have suffered greater negative fitness impacts than females; these studies include 
inbreeding at the cousin level (Ilmonen et al., 2008), inbreeding at the sibling level 
(Meagher et al., 2000), and when animals were fed a moderate sugar diet (Ruff et al. 
2013; Figure S2.2). Male mice might have been affected by the cerivastatin treatment 
more than females due to the competitive nature of males in a polygynous mating system. 
Since OPA studies generate the same outputs, relative fitness can be compared between 
treatments. Results from this study indicate that cerivastatin-exposed male fitness (i.e., 
reproductive success) is approximately 25% less than the male progeny of parents that 
were first cousins (Figure S2.2).  
OPAs have detected adversity in mice exposed to cerivastatin producing results 
without ambiguous interpretation. Unlike proximate-level based approaches of toxicity 
assessment, OPAs allowed for quantification of adverse impacts at the organismal level, 
requiring no assumptions of mechanistic cause. Not only were severe fitness declines 
detected in both males and females when exposed to cerivastatin, these results are 
conservative as all animals within OPAs were placed on the control diet. Thus, all fitness 
declines were caused by previous exposure and the cumulative damage the exposure 
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caused and although the proximate mechanisms of these phenotypes are unknown, OPAs 
could have prompted additional studies that could have led to discovery of the underlying 
mechanisms, which will help in determining if the similar adverse consequences are 
likely to occur in humans. If this had occurred prior to public release, it could have saved 
considerable human suffering and financial losses. 
 
2.6 Conclusion 
OPAs were able to quantify adversities due to cerivastatin exposure that were 
missed during both preclinical and clinical trials. Unfortunately, the failure of available 
screening methods to reveal toxicity led to market availability of cerivastatin for three 
years before it was found to cause unacceptable health consequences and thus was 
recalled. This study validates the ability of OPAs to reveal deleterious effects due to 
pharmaceutical exposures that were missed by current methodologies. OPAs achieve 
their sensitivity because they are unique in that hypotheses concerning specific 
mechanisms of action are not required; rather, whole organismal performance in its 
entirety is measured by OPAs within the context of a seminatural environment. 
Consequently, any toxicity that reduces performance of almost any physiological system 
(e.g., cardiorespiratory, metabolic, or neurological) is likely to be detected as the 
endpoint measures of this assay (such as reproductive success and survival) are integrated 
across physiological systems. Due to their sensitivity and lack of a priori assumptions, 
OPAs could prove useful in toxicity detection during pharmaceutical development, 
screening for potential environmental pollutants, and in quantifying the health 
consequences of nutritional substances.  
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Figure 2.1. Body weight of cerivastatin-exposed founders and controls over time in 
OPAs. A) Cerivastatin-exposed females weighed 5% less than controls across the study, 
which was marginally significant [n =76 mice, observations = 483 (LMM; t = −1.74, p = 
0.09). B) Cerivastatin-exposed males weighed significantly less (10%) than controls 
throughout the study [n = 40 mice, observations = 196 (LMM; t = −3.66, p < 0.001). 
Time point 0 is when animals were released into OPAs. Lines connect means and error 
bars represent standard error.  
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Figure 2.2. Competitive ability of cerivastatin-exposed males and controls. 
Cerivastatin-exposed males occupied 63% fewer territories than control males throughout 
the duration of the experiment [n  = 5 populations, observations  = 130 (GLMM; z = 
−4.55, p < 0.0001)]. Within each enclosure, there were six available territories and a male 
was considered a territorial occupant if > 80% of all male PIT tag readings a particular 
territory belonged to him. On average, control males occupied 49% of the territories, 
cerivastatin-exposed males occupied 18% territories, and the remaining 32% territories 
were left undefended. The undefended territories still contain male mice; however, < 80% 
of male reads at this location belonged to a single individual. Points represent the mean 
number of territories of five populations. To aid in visualization, time points from five-
week intervals have been pooled, except for the first time point consisting of eight weeks. 
For example, time point week eight consists of all data points collected from weeks 1-8; 
time points displayed at week 13 consists of all data points collected from weeks 9-13 
and so on. Lines connect means of the five populations and error bars represent standard 
error. 
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Figure 2.3. Reproductive success of cerivastatin-exposed animals and controls in 
OPAs. A) Cerivastatin-exposed females had 25% fewer offspring than controls 
throughout the study [n = 5 populations, observations = 50 (GLMM; z = −3.70, p < 
0.001)]. B) Similarly, cerivastatin-exposed males sired 41% less offspring than controls 
[n = 5 populations, observations = 50 (GLMM; z = −4.37, p < 0.0001). Female 
reproduction is in terms of total offspring, as mitochondrial markers and multiple 
microsatellite markers were used. Male reproduction is in terms of male offspring, as Y-
chromosomal markers were used. Lines connect means of the five populations at each 
time point for each sex and error bars represent standard error. 
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Figure 2.4. Survivorship of cerivastatin-exposed animals and control animals in 
OPAs.  A) Cerivastatin-exposed females (n = 76) experienced reduced survival compared 
to controls; however, these data were not analyzed due to so few deaths: 100% survival 
of control females and three mortalities in the cerivastatin-exposed treatment. B) 
Cerivastatin-exposed males (n = 40) experienced a threefold increase in mortality than 




































2.9 Supplementary Information 
 
 
Figure S2.1. Image of a seminatural enclosure used in OPA experiments. Each 
enclosure is ~30 m2 and contains 6 territories that are divided by wire mesh. The four 
optimal territories have the large blue bins, which contain multiple dark nesting sites and 
are defendable. The two suboptimal territories consist of light exposed nesting sites. Each 
territory contains food within the chimney-like structures and water (poultry waterers). 
PIT tag antennas (tennis racket like structures) are placed above each feeding site. 
Photograph courtesy Ben Sutter.   
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Figure S2.2. Comparisons of male fitness relative to control counterpart from 
published OPA experiments. Cerivastatin exposure had greater consequences on male 
fitness (reproductive success) when compared with cousin inbreeding, moderate sugar 
consumption, and a selfish gene but suffered less fitness consequences when compared to 
inbreeding at the sibling level ( Meagher et al., 2000; Carroll et al., 2004; Ilmonen et al., 
2008; Ruff et al., 2013). Figure adapted from Ruff et al., 2013.  
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Table S2.1. Mixed model results for litter size and wean weight.  
 
 
Litter Size  
 
GLMM with Poisson distribution and logarithmic link 
(groups = 30; observations = 68) 
Random effects Variance Std. Dev.  
Cage (Intercept) 0.0798 0.2824 
Fixed effects Estimate Std. Error z value Pr( >?z?) 
Intercept (Litter 1)  1.2491  0.1335  9.3550 <0.0001*** 
Treatment (Cerivastatin)  0.0074 0.2124  0.0350   0.9720 
Parity  0.0097 0.0988  0.0980   0.9220 
Treatment (Cerivastatin)×Parity  0.1771  0.1763  1.0040      0.3150 
 
Female Wean Weight 
 
LMM (groups = 27; observations = 124) 
Random effects Variance Std. Dev.  
Cage (Intercept) 1.3423 1.1586 
Cage (Slope) 0.2616 0.5115 
Fixed effects Estimate Std. Error t value Pr( >?t?) 
Intercept (Litter 1) 10.8131 0.3517 30.7420 <0.0001*** 
Treatment (Cerivastatin)   0.3676 0.5445   0.6750   0.5060 
Parity   0.2769 0.2134   1.2980   0.2180 
Treatment (Cerivastatin)×Parity  -0.2998 0.3725  -0.8050   0.4300 
 
Male Wean Weight  
 
LMM (groups = 29; observations = 136) 
Random effects Variance  Std. Dev.  
Cage (Intercept) 0.9751 0.9875 
Cage (Slope) 0.3131 0.5596 
Fixed effects  Estimate Std. Error t value Pr( >?t?) 
Intercept (Litter 1) 11.9781 0.3381 35.4200 <0.0001*** 
Treatment (Cerivastatin)  0.3805 0.5378   0.7100   0.4840 
Parity  0.4470 0.2675   1.6700   0.1110 
Treatment (Cerivastatin)×Parity -0.2711 0.4817  -0.5600   0.5790 
*** Indicates a p value < 0.001.  
 44 
Table S2.2. Linear mixed model results for body weight over time within OPAs. 
 
Female Body Weight  
 
LMM (group = 76; observations = 438) 
Random effects Variance  Std. Dev.  
Individual (Intercept) 0.4176 0.6462 
Individual (Slope) 0.0209 0.1447 
Population (Intercept) 1.8593 1.3636 
Population (Slope) 0.0024 0.0489 
Fixed effects  Estimate Std. Error t value Pr( >?t?) 
Intercept (Week 0) 19.8851 0.7814 25.4490  <0.0001*** 
Treatment (Cerivastatin) -1.1998 0.6917  -1.7350    0.0857 · 
Time  0.4309 0.0425 10.1400  <0.0001*** 
Treatment (Cerivastatin)×Time  0.0114 0.0519   0.2200    0.8263 
 
Male Body Weight  
 
LMM (group = 40; observations = 196) 
Random effects Variance  Std. Dev.  
Individual (Intercept) 1.7187 1.3110 
Population (Intercept) 0.8147 0.9026 
Fixed effects  Estimate Std. Error t value Pr( >?t?) 
Intercept (Week 0) 21.3518 0.5636 37.8900  <0.0001*** 
Treatment (Cerivastatin) -2.0497 0.5605 -3.6600    0.0005*** 
Time 0.1482 0.0156  9.5300  <0.0001*** 
Treatment (Cerivastatin)×Time 0.0246 0.0235  1.0500    0.2970 








Male Competitive Ability 
 
GLMM with binomial distribution and logit link (group 
= 5; observations = 130) 
Random effects Variance Std. Dev.  
Population (Slope) 0.0570 0.2387 
Fixed effects Estimate Std. Error z value Pr( >?z?) 
Intercept (Week 3) -0.0260 0.2237 -0.1160   0.9080 
Treatment (Cerivastatin) -1.4625 0.3215 -4.5490 <0.0001*** 
Time   0.0125 0.0126  0.9890   0.3230 
Treatment (Cerivastatin)×Time -0.0235 0.0209 -1.1230   0.2620 
· Indicates a p value <0.10, *** < 0.001. 
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Table S2.4. Generalized linear mixed model results for reproduction over time.  
 
 
Female Reproduction  
 
GLMM with Poisson distribution and logarithmic link 
(group = 5; observations = 50) 
Random effects Variance Std. Dev.  
Population (Intercept) 0.11328 0.3366 
Fixed effects Estimate Std. Error z value Pr( >?z?) 
Intercept (Week 8)  3.4221 0.1622  21.1020 <0.0001*** 
Treatment (Cerivastatin) -0.3394 0.0917  -3.7000   0.0002*** 
Time  0.0163 0.0048   3.3910   0.0007*** 





GLMM with Poisson distribution and logarithmic link 
(group = 5; observations = 50) 
Random effects Variance Std. Dev.  
Population (Intercept) 0.1345 0.3668 
Fixed effects Estimate Std. Error z value Pr( >?z?) 
Intercept (Week 8)  2.7980 0.1832  15.2690 <0.0001*** 
Treatment (Cerivastatin) -0.5858 0.1341  -4.3660 <0.0001*** 
Time  0.0162 0.0063   2.5820   0.0098** 
Treatment (Cerivastatin)×Time  0.0051 0.0103   0.4910   0.6233 
** Indicates a p value < 0.01, *** < 0.001.  
 
2.10 Statistical Analyses 
Weight of offspring at weaning was analyzed with a linear mixed-effects model. 
This model assessed the effects of treatment, time, and the interaction of time and 
treatment. The model intercept was set to litter one, as that was when the data collection 
started. Treatment, parity, and their interaction were treated as fixed effects while cage 
was modeled as a random effect with a random intercept generated for each. Sexes were 
analyzed separately. A normal distribution was assumed because weight data are 
continuous. Sample sizes used to assess weight differences include: 45 daughters from 11 
cerivastatin cages, 79 daughters from 16 control cages for a total of 124 observations 
from 27 cages; 48 sons 12 cerivastatin cages and 88 sons from 17 control cages for a total 
of 136 observations from 29 cages.  
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Litter size data are discrete counts and therefore were analyzed with a generalized 
linear mixed model (GLMM) with a Poisson distribution and logarithmic link. This 
model assessed the effects of treatment, time, and the interaction of time and treatment. 
The model intercept was set to litter one, as that was when the data collection started. 
Litter size data were collected at weaning. Treatment, parity, and their interaction were 
treated as fixed effects while cage was modeled as a random effect with a random 
intercept generated for each. There were 24 cerivastatin-exposed litters from 12 cages 
and 44 control litters from 18 cages for a total of 68 observations from 30 cages used in 
this analysis.  
Body weight was analyzed with a linear mixed-effects model. This model 
assessed the effects of treatment, time, and the interaction of time and treatment on the 
116 population founders. Sexes were analyzed separately. A normal distribution was 
assumed because weight data are continuous. Treatment, time, and their interaction were 
modeled as fixed effects and individual and population were modeled as random effects 
with random slopes and intercepts generated for each. The intercept was set at week zero, 
as this was when founders were released into the enclosures and at which collected of 
weight data from OPAs began. Collection of founder weight data continued on surviving 
individuals at each pup sweep. There were a total of 438 observations from 76 females 
and 196 observations from 40 males collected throughout the experiment.  
Reproductive outputs were in terms of total offspring and thus are discrete data. 
These data were analyzed with a generalized linear mixed model with a Poisson 
distribution and logarithmic link. The model assessed the effects of treatment, time, and 
the interaction of treatment and time on the population level. These effects were set as 
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fixed effects in the model and population was set as a random effect with random 
intercept calculated for each. The intercept was set at week eight, as that was when the 
first collection period or pup sweep occurred. Reproductive output for each treatment was 
measured five times over the course of the 28-week study in each of the five independent 
populations for a total of 50 observations. Female reproductive output was analyzed in 
terms of total offspring and male reproductive success was analyzed in terms of male 
offspring.  
To assess the probability of territorial ownership, a generalized linear mixed 
model was used. As a territory can be defended or not, a binomial distribution was used 
with a logit link. There are six territories within a population and were either occupied by 
cerivastatin-exposed males, control males, or unoccupied. A total of 130 observations 
were collected from five populations and analyzed throughout the study. The model 
assessed the effect of treatment, time, and their interaction. These effects were set as 
fixed effects and population was set as a random effect with a random intercept generated 
for each. The model intercept was set to week three, as that was when data existed for 
each population.  
A multivariate Cox proportional hazard model analyzed survival of founders. 
Impacts of treatment and population were examined in the model. Individuals that 
survived the length of the study or that were intentionally removed from the study were 
censored. Female survival was not analyzed because of 100% survival in control females 
and only three mortalities in the cerivastatin treatment (76 individuals, 3 events). For 
male survival analyses, 40 individuals were analyzed, 15 events and 25 censorings.  
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Cox proportion hazard models were conducted in JMP 9.0.3 (SAS institute Inc., 
Cary NC. Both LMMs and GLMMs were conducted in R 3.0.2 using the lme4 library 
(Bates et al., 2014, R Development Core Team 2013). P-values were calculated for LMM 
with the Swatterthwaite approximation under the lmerTest function (Kuznetsova et al., 
2013). For all mixed models, several candidate models were fit to the data. These models 
varied in terms of random effects that estimated both intercept and/or slope. For each 
analysis, the model that explained some of the variance with random effects and had the 
lowest Akaike Information Criterion (AIC) score was reported. Neither the significance 
of a fixed effect nor the magnitude of the significance varied between models.  
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LOW-DOSE PAROXETINE EXPOSURE CAUSES LIFETIME FITNESS DECLINES 




We utilized organismal performance assays (OPAs), a novel toxicity assessment 
method, to assess the safety of paroxetine. Paroxetine is a selective serotonin reuptake 
inhibitor (SSRI) that is currently available on the market and is suspected of causing 
congenital malformations in babies born to mothers who take the drug during the first 
trimester of pregnancy. OPAs utilize genetically diverse wild mice (Mus musculus) to 
evaluate competitive performance between experimental and control animals as they 
compete amongst each other for limited resources in seminatural enclosures. Performance 
measures included reproductive success, male competitive ability, and survivorship. 
Paroxetine-exposed males weighed 13% less, had 44% fewer offspring, dominated 53% 
fewer territories, and experienced a 2.5 fold increased trend in mortality when compared 
with controls. Paroxetine-exposed females had 65% fewer offspring early in the study, 
but rebounded at later time points. In breeding cages, paroxetine-exposed breeders took 
2.3 times longer to produce their first litter and pups of both sexes experienced reduced 
weight when compared with controls. Low-dose paroxetine-induced health declines 
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detected in this study were undetected in preclinical trials with doses 2.5-8 times higher 
than human therapeutic doses. These data indicate that OPAs provide superior sensitivity 
compared to conventional approaches and demonstrate that OPAs could be a useful tool 
in safety testing during pharmaceutical development.  
 
3.2 Introduction 
Selective serotonin reuptake inhibitors (SSRIs) are the most commonly prescribed 
antidepressants with 74% of depression cases receiving SSRIs for therapy (Schmidt et al. 
1997). Paroxetine [Paxil®, GlaxoSmithKline (GSK), Brentford, England] became 
commercially available in 1992 and has been used to treat patients with depression, 
anxiety, and other mood disorders. Paroxetine, along with other SSRIs, are suspected of 
causing congenital cardiac defects and pulmonary hypertension when a fetus is exposed 
during the first trimester; however, these epidemiological studies are controversial where 
some studies find correlative evidence (Williams and Wooltorton 2005, Bérard et al. 
2007, Diav-Citrin et al. 2008, Ellfolk and Malm 2010) and others do not (Kulin et al. 
1998, Källén and Otterblad Olausson 2007). Despite this controversy, in 2005, the Food 
and Drug Administration (FDA) requested that paroxetine be labeled as a class D drug 
(positive evidence of human fetal risk) and issued a warning that paroxetine exposure in 
the first trimester may potentially cause birth defects (FDA 2005).  
The preclinical assessment of paroxetine followed the typical protocol in which 
the drug was tested to determine whether it was mutagenic, carcinogenic, teratogenic, or 
if it caused infertility (GSK 2013). No genotoxic effects were detected in rodent cells, 
and tumors were only detected in mice and rats at doses 2-3.9 times the maximum 
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recommended human dose (GSK 2013). Teratogenicity was not assessed in mice and no 
teratogenic effects were in observed in rats when given a dose > 8 times higher than 
human therapeutic doses (GSK 2013). Paroxetine effects on fertility were not assessed in 
mice but found to impair rat fertility only at high doses: when females were given 2.5 
fold higher and when males were given > 8 times higher than human therapeutic doses 
(GSK 2013). After successful completion of preclinical assessment, paroxetine was 
deemed safe and continued onto clinical trials until it was released onto the market.  
Like paroxetine, many medications once considered safe are found to cause 
unacceptable health consequences after public release. On average, 73% of 
pharmaceuticals fail during clinical trials (Lipsky and Sharp 2001) and 10% of FDA 
approved pharmaceuticals are recalled after market release (Schuster et al. 2005), despite 
the 12-15 years of research and $1.4 billion average cost associated with each drug 
during development (Miller 2012). One cause of the high pharmaceutical failure rate is 
the inability of current toxicity assessment methods to detect cryptic adversities during 
preclinical trials, particularly those present at low doses and/or those occurring at low 
incidences. 
We have developed a novel toxicity assessment research method that may be 
useful during preclinical assessment, known as the organismal performance assay (OPA). 
In several instances, OPAs have proven capable of detecting mammalian health declines 
with higher sensitivity than current in vivo and in vitro approaches. OPAs utilize 
genetically diverse wild-derived mice (Mus musculus) that compete amongst each other 
for limited resources in seminatural enclosures, which allows for direct competition 
between treatment and control individuals. Individual performance is measured in terms 
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of Darwinian fitness (i.e., reproductive success) and components leading to fitness (i.e., 
survivorship and male competitive ability). OPAs are sensitive because they challenge 
most physiological systems synergistically and in order for individuals to be successful, 
high performance from these physiological systems is required.  
OPAs have previously been used to quantify the adverse effects of sibling-level 
and cousin-level inbreeding (Meagher et al. 2000, Ilmonen et al. 2008), harboring a 
selfish gene (Carroll et al. 2004), and recently, they were the first assay to reveal the 
adverse effects of added sugar consumption at human-relevant levels (Ruff et al. 2013). 
In all of these studies, OPAs found substantial deleterious effects that were missed by 
current methodologies. OPAs contain an internal control (direct competition between 
treatment and control animals), which prevents OPAs from generating false positives.  
Here OPAs are used to determine if paroxetine exposure near human therapeutic 
doses during in utero and into early adulthood cause fitness declines in wild mice. Our 
findings address the current lack of information concerning long-term paroxetine 
exposure on health at the organismal level. If paroxetine exposure adversely affects any 
physiological system, we hypothesize that exposed individuals will suffer survival and 
reproduction declines relative to control individuals while competing within OPAs. 
Furthermore, while generating animals for OPAs, we assessed whether paroxetine 






3.3 Materials and Methods 
3.3.1 Animals. Wild-derived outbred house mice were used in this experiment. 
Unlike many genetically inbred mouse strains, wild mice have behavioral characteristics 
that allow them to function in natural and seminatural environments (Nelson et al. 2013). 
In this experiment, individuals were from the 12th generation of the colony described by 
Meagher et al. 2000. Genetic diversity of this colony was assessed in the 11th generation 
and found to be comparable to wild populations (Cunningham et al. 2013). Within OPAs 
and breeding cages, individuals were provided access to food and water ad libitum and 
maintained on a 12:12 hour light:dark cycle. All procedures were approved by the 
University of Utah IACUC. 
3.3.2 Drug exposure. Dosing was achieved by incorporating 7.5 g paroxetine 
(GSK, molecular formula: C19H20FNO3?HCl) into 50 kg of rodent chow (TD.130006; 
Harlan Teklad, Madison, WI). Mice consuming an average of 3 g of food per day and 
weigh 20 g will ingest 0.45 mg per day or 22.5 mg/kg/day. Using a standard metabolic 
rate conversion factor, this is equivalent to a human dose of 1.82 mg/kg/day, or a daily 
dose of 109.20 mg, assuming the average human weighs 60 kg (Reagan-Shaw et al. 
2008). Given that paroxetine is prescribed in the range of 20 – 60 mg/day (Dunner and 
Dunbar 1992, GSK 2013), our dose is 1.82 fold higher than human therapeutic doses, yet 
lower than doses used in previous animal studies (Coleman et al. 1999, Rayburn et al. 
2000, El-gaafarawi et al. 2005). One study determined that a paroxetine dose of 30 
mg/kg/day achieved serum levels in mice that were comparable to human serum levels 
when taking the highest therapeutic dose (Coleman et al. 1999).   
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Sixty breeder pairs were selected for this experiment; 20 pairs were exposed to 
paroxetine while the remainder served as controls. The asymmetry in cage number is due 
to the production of additional control animals for another study. Prior to breeding, 
animals were individually housed and provided with their respective diets. Females were 
exposed to paroxetine eight days prior and males five days prior to breeding. Breeding 
pairs were kept together until a maximum of four litters were produced to ensure enough 
animals for OPA assessment. At 28 days of age, pups were weaned and housed in same-
sex sibling cages. Upon weaning, individual weight, sex, and litter size data were 
collected and paroxetine exposure continued until animals were released into enclosures.  
The duration of paroxetine exposure maximized the ability of OPAs to detect health 
consequences because once animals were released into the seminatural enclosures, they 
were all fed the control diet as currently, we are unable to keep animals on their 
respective diets while they are free ranging during OPAs. Upon release into OPAs, both 
paroxetine-exposed and control animals were provided with the control diet ad libitum. 
Switching the paroxetine-exposed animals to the control diet was the most conservative 
approach of detecting fitness impacts, because OPAs would then be assessing cumulative 
damage.   
3.3.3 OPA enclosures. Enclosures have previously been described in Ruff et al. 
2013. Briefly, the indoor enclosures are approximately 30 m2 and consist of two types of 
territories, optimal (n = 4) and suboptimal (n = 2). Each optimal territory contained a 
defendable box with multiple dark nesting sites and direct access to food. Suboptimal 
territories contained two nesting boxes exposed to light and had indirect access to food. 
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Territories were separated by hardware mesh that is easily climbed, but added an element 
of spatial complexity (Figure S3.1).  
Five independent OPA populations were established and maintained for 28 
weeks. OPA populations consisted of eight males and 14-16 females, for a total of 116 
animals (40 males, 76 females); these animals are referred to as population founders. Half 
of the individuals of each sex were paroxetine-exposed while the remainder served as 
controls; this population structure allows paroxetine individuals to directly compete with 
control individuals for mates, resources, and territories. Enclosure space and population 
size created a population density within the range observed in the wild (Sage 1981).  
Upon OPA release, male mice were on average 14.3 (SD ± 4.7) weeks old and 
females were 18.9 (± 7.0) weeks old. Males were released into enclosures with non-
experimental females to allow males to establish territories, which prevented incidental 
breeding during the initial social chaos of population formation. Nonexperimental 
females were then removed and replaced with experimental females one week later. Male 
population founders were unrelated at the cousin level or above with the exception that 
three populations consisted of one set of brothers and one population consisted of two 
sets of brothers. Similarly, all populations consisted of sister pairs and four populations 
consisted of sister trios. At most, one male per treatment was in a population containing 
two of his sisters. When relatedness was present, it was balanced between treatments.   
3.3.4 Reproductive success. Reproductive success of founders was determined by 
removing and genotyping all offspring in OPAs. Every five weeks, research personnel 
conducted a “pup sweep,” in which all offspring were removed, sacrificed, and had a 
tissue sample collected for genetic analyses. As the gestation period of mice is three 
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weeks, the first pup sweep occurred on week eight, then every sweep following occurred 
on five-week intervals; this sweep schedule prevented offspring from reaching sexual 
maturity within OPAs. A total of 872 samples were collected with an average of 174.4 ± 
38.1 (M ± S.D.) offspring per population. 
 In three of the five populations, reproductive success was determined on a 
population-level by examining sex-specific allelic variants that have been previously 
described in Meagher et al. 2000. Briefly, nonoverlapping allelic variants were assigned 
to founders of each treatment (paroxetine-exposed or control). Females were selected 
upon allelic variants of the mitochondrial genome and males upon the Y-chromosome. 
The output of male reproductive success in these populations is based solely upon male 
offspring, as females do not possess Y-chromosomes. Reciprocal markers were assigned 
across populations to control for confounding effects. Mitochondrial genotypes were 
assessed in 626 samples (three of five populations) and obtained for 100% of offspring. 
Y-chromosome genotypes were assessed in all five populations to determine male 
reproductive output and the sex ratio of offspring. Of the 872 offspring, 414 Y- 
chromosome genotypes were obtained suggesting that 95% of all males were typed if the 
sex ratio was 1:1; successfully genotyping nearly all of the progeny allowed for a 
thorough analysis of founder reproductive success.  
To gain a better understanding of individual-level reproductive success, parentage 
analysis was conducted in two populations using multiple microsatellite loci. Female 
reproductive success determined by microsatellite loci were converted to population level 
readouts (i.e., number of pups per treatment rather than number of pups per individual) 
and combined with the mitochondrial data for analysis. Between six and 17 autosomal 
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microsatellite loci were amplified, scored, and analyzed in a stepwise fashion. Loci used 
were: d1mit251, d1mit449, d3mit22, d3mit312, d3mit333, d4mit205, d5mit139, 
d6mit138, d9mit232, d9mit251, d12mit277, d14mit128, d17mit24, d17mit62, d17mit82, 
d17mit102, and d19mit110. Primer sequences were obtained from the Mouse Genome 
Informatics website, The Jackson Laboratory, Bar Harbor Maine 
(http://www.informatics.jax.org/ accessed March 2014). Primers were tagged with either 
CY-5 or CY-3 fluorescent dye. DNA samples were PCR-amplified and then run on 14” x 
17”, 6.25% denaturing acrylamide gel at 40 W for three to seven hours (locus dependent). 
Gels were imaged on a Typhoon Scanner 8600 using ImageQuant software (Amersham 
Biosciences, Piscataway, NJ). 
 Parentage via multiple microsatellites was assigned using Cervus 3.0 
(Kalinowski et al. 2007). Genotypes of all candidate mothers and fathers and all offspring 
within each population were used to calculate allele frequencies. Simulations were run 
10,000 cycles with an error rate of 1% to derive a delta score. Assigned parents were 
accepted when the trio confidence of mother, father and offspring was 95%. Using this 
rule, 91% (187/205) of one population was genotyped and 75% (147/195) of the second 
population was genotyped.  
3.3.5 Male competitive ability. For identification purposes, all animals were given 
a unique ear punch and received a passive integrated transponder (PIT) tag  (TX1400ST, 
BioMark, Boise, ID) prior to OPA release. Two sets of PIT tag antenna and readers 
(FS2001F-ISO, BioMark, Boise, ID) collected data on OPA populations and were rotated 
twice weekly among concurrent populations. Antennas were placed on top of feeding 
stations in each territory of an enclosure. PIT tag data were downloaded to a computer 
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containing data logging software (Minimon, Culver City, CA). A male was assigned as 
an territorial occupant when he possessed > 80% of the total reads at a particular location. 
PIT tag data were collected on female mice, but were not analyzed due to the general lack 
of information on female dominance behavior. 
3.3.6 Survivorship. Noninvasive health checks were performed daily and 
extensive enclosure checks every five weeks during pup sweeps. Extensive enclosure 
checks were limited as to avoid disrupting territoriality that increases the rate of 
infanticide. When deceased founders were observed, they were removed from the 
enclosures. The date of death was estimated upon the condition of the corpse. Severely 
decomposed founders were given a date half way between the date the individual was 
found and the last date the PIT tag of that individual was recorded.  
3.3.7 Statistical analyses. Cox proportional hazard (PH) models were used for 
OPA survivorship and the time to produce first litter from cage data (JMP 9.0.3, SAS 
institute Inc., Cary NC). Generalized linear mixed models (GLMM) were used for litter 
size, reproductive success, and male competitive ability (R 3.0.2). Reported SEMs are 
asymmetric because values have been back-transformed from logarithmic data. Linear 
mixed models (LMM) were used for wean weight and OPA body weight (R 3.0.2). A 




3.4.1 Breeding cage measures. Paroxetine-exposed breeders took 2.3 times longer 
to produce their first litter when compared to controls (PH; χ2 = 3.98, p < 0.05; Figure 
 61 
3.1); however, litter size was not affected by treatment (GLMM; z = −0.58, p = 0.56). 
Control breeders produced an average of 4.54 (SEM +0.45, −0.41) pups in their first 
litter, while paroxetine-exposed breeders produced 4.09 (+0.83, −0.75) pups in their first 
litter. No effect of time (GLMM; z = −0.70, p = 0.49) or time by treatment was detected 
(GLMM; z = 0.65, p = 0.52). For a complete readout of mixed model results for breeding 
cage data, see Table S3.1.  
Offspring from paroxetine-exposed breeders weighed less at weaning than 
offspring from control breeders. Paroxetine-exposed female offspring weighed 16% less 
than controls with an average of 8.81 g (SEM ± 0.52), whereas control female offspring 
weighed 10.77 g (± 0.31) (LMM; t = −3.70, p < 0.001; Figure 3.2A). No effect of parity 
on weight occurred (LMM; t = 1.80, p = 0.11), nor was there an interaction between 
treatment and parity (LMM; t = 0.43, p = 0.68). Male offspring from paroxetine-exposed  
 breeders weighed 25% less than controls (LMM; t = −3.83, p < 0.001; Figure 3.2B), with 
pups weighing 9.63 g (± 0.73) and control male offspring weighing 12.39 g (± 0.37). No 
effect of parity (LMM; t = 1.34, p = 0.18) or parity by treatment was detected (LMM; t = 
0.41, p = 0.69).    
3.4.2 OPA measures. Within OPAs, paroxetine exposure had differential affects 
on body weight between the sexes. Upon OPA release (model intercept, week zero), no 
differences were detected in body weight of paroxetine-exposed and control females 
(LMM; t = −1.04, p = 0.30; Figure 3.3A). Paroxetine-exposed females weighed on 
average 19.39 g (SEM ± 1.03) while controls weighed 20.46 g (± 1.25). Both groups of 
females gained weight over time (LMM; t = 5.12, p < 0.01), due to pregnancy, and no 
interaction of time by treatment was detected (LMM; t = −1.64, p = 0.11). Paroxetine-
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exposed males weighed less (LMM; t = −3.94, p < 0.001; Figure 3.3B) than controls 
upon OPA entrance. Paroxetine-exposed males weighed 18.42 g (± 0.87) and controls 
weighed 21.75 g (± 0.90). Both groups gained weight over time (LMM; t = 2.60, p = 
0.05), but no time by diet interaction was detected (LMM; t = −0.22, p = 0.83), indicating 
that paroxetine-exposed males weighed 13% less than controls throughout the duration of 
the experiment. For a complete readout of mixed model results for OPA body weight 
measures, see Table S3.2. 
Female reproductive success was hindered by paroxetine exposure (GLMM; z = 
−5.03, p < 0.0001; Figure 3.4A) at week eight (model intercept), where mean 
reproduction of paroxetine-exposed females was 65% less than controls. Paroxetine-
exposed females had an average of 10.68 (+1.44, −1.26) offspring per population, while 
control females had an average of 20.16 (+1.63, −1.51) offspring per population. No 
effect of time was detected (GLMM; z = −0.63, p = 0.53). However, there was a 
significant interaction between time and treatment (GLMM; z = 3.95, p < 0.0001), 
suggesting that paroxetine-exposed female reproduction increased over time. As exposure 
had significant and opposing effects in regards to the intercept and slope of the linear 
model, post-hoc t tests were conducted at each pup sweep and a significant difference 
was only detected at week eight (p < 0.05). For a complete readout of mixed model 
results for OPA reproduction and competitive ability, see Table S3.3. 
Paroxetine exposure also negatively affected male reproductive success as 
measured by male offspring, where paroxetine-exposed males had 44% fewer offspring 
than controls (GLMM; z = −2.72, p < 0.01; Figure 3.4B). At week eight (model 
intercept), mean reproduction of paroxetine-exposed males was on average 5.25 (SEM 
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+1.07, −0.90) male offspring per population per population. Control males sired an 
average of 8.71 (+1.09, −0.96) male offspring per population. Male founders from both 
treatments had an increase in reproductive success over time (GLMM; z = 2.16, p = 
0.03), but no time by treatment interaction was detected (GLMM; z = −0.51, p = 0.61), 
indicating that paroxetine-exposed males had reduced reproductive success throughout 
the study.  
Male competitive ability was adversely impacted by paroxetine exposure, where 
paroxetine males occupied 53% fewer territories than controls. At week three (model 
intercept) control males occupied 47% of the territories, while paroxetine-exposed males 
only occupied 22% territories (GLMM; z = −4.11, p < 0.0001; Figure 3.5), leaving 31% 
of the territories undefended. The percent of undefended territories is not unusual because 
2/6 (or 33%) were suboptimal and often difficult to defend. There was no difference in 
territorial occupancy over time (GLMM; z = −0.14, p = 0.89), nor was there a difference 
in the time by diet interaction (GLMM; z = 0.18, p = 0.86), indicating that the differential 
acquisition of territories by control and paroxetine-exposed males was consistent across 
the study.  
No differences were detected in mortality between paroxetine-exposed and 
control females (PH; χ2 = 0.66, p = 0.42; Figure 3.6A). Female mortality rates did not 
differ in replicate populations (PH; χ 2 = 3.51, p = 0.48), nor was there a difference in the 
effect of treatment among populations (PH; χ 2 = 3.35, p = 0.50). A marginally statically 
significant trend was detected in which male mortality was increased approximately 2.5 
by paroxetine exposure (PH; χ 2 = 3.27, p = 0.07; Figure 3.6B). Male mortality rate did 
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not differ in replicate populations (PH; χ 2 = 5.24, p = 0.26), nor was there a difference in 
the effect of treatment among populations (PH; χ 2 = 3.77; p = 0.44).  
 
3.5 Discussion 
We detected numerous adverse effects when animals were exposed to paroxetine 
in utero through early adulthood. In cages, breeders took 2.3 times longer to produce 
their first litter and offspring from these breeders experienced reduced wean weight when 
compared with controls. Additionally, OPAs revealed several deleterious effects in 
paroxetine-exposed males in which they experienced 13% reduced body weight, had 44% 
reduced reproductive success, occupied 53% fewer territories, and showed a marginally 
significant 2.5-increased mortality rate. Paroxetine-exposed females too suffered reduced 
reproductive success by 65%, but only at the initial pup sweep, suggesting they might be 
recovering from their paroxetine exposure. OPAs revealed numerous health 
consequences at the organismal level, which were missed by conventional methods; these 
phenotypes are likely to be caused by paroxetine disrupting several mechanisms, whose 
descriptions follow.  
Paroxetine-exposed breeders took 2.3 times longer to produce their first litter 
when compared with controls, which could be caused by paroxetine interfering with 
hormones that regulate the female reproductive system. Within the estrus cycle, a surge 
of luteinizing hormone (LH) occurs at the time of ovulation allowing for fertilization of 
the ovum. A reduction in LH levels, along with other important reproductive hormones 
(i.e., estradiol, progesterone) have been observed after paroxetine exposure in female rats 
(El-gaafarawi et al. 2005). These hormones play an important role in regulating the 
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function of the female reproductive system and alterations of these hormones may have 
caused delayed reproduction. 
Although litter size did not differ between treatments in breeding cages, 
paroxetine-exposed founder females had 65% fewer offspring, but only at the first pup 
sweep in OPAs. This finding suggests that OPAs are more sensitive than cages as they 
were able to detect this fitness consequence, which was invisible under standard housing. 
It is likely that the damage from previous paroxetine exposure decreased over time as 
exposure ceased at the time of OPA release, which may in part explain the increase in 
reproductive success of exposed females as the study progressed. However, the initial 
reduction in reproduction may also be explained by the endocrine disruptions responsible 
for the delayed reproduction experienced by females in cages. The data indicating that the 
negative effects of paroxetine exposure on reproduction decrease over time suggest that 
the negative effects on female reproduction is reversible.  
Wean weight was reduced in both male and female offspring when breeding pairs 
were exposed to paroxetine. Reduced birth weight has been detected in previous rodent 
(Coleman et al. 1999, Rayburn et al. 2000) and human studies (Diav-Citrin et al. 2008). 
Upon OPA entrance, the affect of treatment on female weight was no longer detected, 
although a trend was observed wherein paroxetine-exposed females gained weight at a 
decreased rate relative to controls. This trend of reduced weight within OPAs may be 
explained by reduced pregnancies in the paroxetine-exposed females. Like females, 
paroxetine-exposed males weighed less at weaning and continued to weigh less 
throughout all time points within the OPAs.  
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Paroxetine-exposed males were less competitive and dominated 53% fewer 
territories than controls. Decreased body weight may be a partial cause of the decreased 
competitive ability, as males must engage in physical competitions to obtain and defend 
territories. The benefit of a relatively larger body weight on competitive ability is well 
established to be advantageous in territorial acquisition and defense in mice [e.g., (van 
Zegeren 1980, Krackow 1993)]. Another possible explanation of why paroxetine-exposed 
males are less competitive is that the drug may have altered their hormonal signaling. 
Testosterone plays a large role in male behavior, especially competitive behaviors in 
mice (Zielinski and Vandenbergh 1993). El-Gaafarawi et al. (2005) found that when male 
rats were exposed to paroxetine, serum levels of testosterone were significantly reduced 
and estradiol levels were increased. Although a proximate mechanistic cause of 
paroxetine is suggested here, the adverse effects on organismal competition have not 
previously been demonstrated. It is likely that multiple factors contribute to these changes 
including hormonal alterations that may have changed normal behaviors, such as the 
desire to participate in intrasexual competition.  
 Paroxetine-exposed males experienced reduced reproductive success, producing 
44% fewer offspring than controls. Previous OPA studies reveal that dominant males sire 
> 80% of offspring within the enclosures (Carroll et al. 2004) and therefore, differences 
in competitive ability likely explain a large portion of the differential reproduction. A 
trend was also observed in which paroxetine-exposed males suffered greater mortality 
and thus even if not significant alone, it does contribute to the reduced reproduction. 
Another possibility is that paroxetine has direct negative impacts on the male 
reproductive system. Paroxetine exposure has been shown to cause reduced sperm count 
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(Baldwin et al. 1989, El-gaafarawi et al. 2005) and an increased rate of sperm 
abnormalities in rats (El-gaafarawi et al. 2005). Altered hormone levels such as decreased 
follicle stimulating hormone (FSH), LH, and testosterone have been documented in 
paroxetine-exposed rats (El-gaafarawi et al. 2005) and these hormones are important in 
spermatogenesis (Kovacs 2012). Decreased competitive ability, increased mortality, and 
insults to sperm production are likely causes that lead to a decline in male reproductive 
success. 
Although fitness declines were detected in both sexes, male mice exposed to 
paroxetine suffered greater adversity than did females. Differential health consequences 
between sexes have been detected with the use of OPAs in previous studies. Males have 
suffered greater negative fitness impacts than females in three previous OPA studies, 
inbreeding at the cousin level (Ilmonen et al. 2008), inbreeding at the sibling level 
(Meagher et al. 2000), and when animals were fed a moderate sugar diet (Ruff et al. 
2013;  Figure S3.2). Male mice may have been adversely affected by the paroxetine 
treatment more so than females due to the competitive nature of their social ecology. 
Since OPA studies generate the same outputs, relative fitness can be compared between 
treatments and for example, results from this study indicate that paroxetine-exposed male 
fitness (i.e., reproductive success) is ~25% less than the inbred males born to parents of 
first cousins (Figure S3.2).  
 
3.6 Conclusions 
Despite the controversial evidence of paroxetine-induced birth defects in humans, 
we detected health consequences in mice that underwent low-dose paroxetine exposure in 
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utero and into early adulthood. While paroxetine-exposed females recovered from the 
deleterious effects after the exposure ceased but males continued to experience severe 
adverse health consequences throughout their lifetime. Here, OPAs indicate that 
paroxetine exposure causes adversity without ambiguous interpretation and we can 
conclude that paroxetine exposure in utero and into early adulthood negatively affects the 
health of the resulting offspring, particularly male offspring. These risks should be 
considered while deciding whether or not to take paroxetine during pregnancy. 
There is currently a great need for a more sensitive toxicity assessment assay that 
provides results without ambiguous interpretation of adversity. Data presented here 
suggest OPAs will fulfill that role and will be useful during pharmaceutical development 
and if implemented have the potential to significantly reduce the failure rate during 
clinical trials. Likewise, OPAs may also be useful in two other divisions of toxicity 
assessment: 1) screening for possible environmental pollutants before humans and 
wildlife undergo long-term exposures under the assumption that they are safe and 2) 
assessing the health consequences of dietary components. Undeniably, the revelation that 
low dose paroxetine-exposure negatively affected weight, competitive ability, 
reproduction, and survival is evidence that OPAs have the potential to identify and 
quantify toxicities that have escaped detection in previously used systems. These 
organismal phenotypes can now form the basis for investigations to discover the 
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Figure 3.1. Time until first litter of paroxetine-exposed and control breeders. In 
breeding cages, paroxetine-exposed breeders (n = 20) took 2.3 times longer to produce 
their first litter when compared with control breeders [n = 40, (PH; χ2 = 3.98, p < 0.05)]. 



















































Figure 3.2. Offspring wean weight from paroxetine-exposed and control breeders. 
A) Female offspring from paroxetine-exposed breeders weighed 16% less than controls 
[n = 24 cages, obs = 134 (LMM; t = −3.70, p < 0.001)]. B) Male offspring from 
paroxetine-exposed breeders weighed 25% less than male offspring from control breeders 
[n = 25 cages, obs = 111 (LMM; t = −3.83, p < 0.001)]. Lines represent means and error 









































Figure 3.3. Body weight of paroxetine-exposed and control founders within OPAs 
over time. A) Female body weight did not differ between treatments [n = 76 mice, obs = 
386 (LMM; t = −1.04, p = 0.30)]. B) Paroxetine-exposed males weighed 13% less than 
controls over the duration of the study [n = 40 mice, obs = 179 (LMM; t = −3.94, p < 
0.001)]. Lines connect means and error bars represent standard error. 
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Figure 3.4. Reproductive success of paroxetine-exposed and control founders in 
OPAs. A) Paroxetine-exposed females had 65% fewer offspring at week eight [n = 5 
populations, obs = 50 (GLMM; z = −5.03, p < 0.0001)], but had more offspring over time 
(GLMM; z = 3.95, p < 0.0001). This was confirmed with post-hoc tests indicating that at 
week eight, reproduction was significantly different; however, no difference was seen at 
any other time. B) Paroxetine-exposed males had 44% fewer male offspring compared 
with controls across the study [n = 5 populations, obs = 50 (GLMM; z = −2.72, p < 0.01). 
Lines connect means of the five populations at each time point for each sex and error bars 
represent standard error. 

















































































Figure 3.5. Competitive ability of paroxetine-exposed and control males over time 
within OPAs. Paroxetine-exposed males occupied 54% fewer territories than controls 
over the duration of the study [n = 5 populations, obs = 122 (GLMM; z = −4.11, p < 
0.0001). Control males occupied 47% of the territories paroxetine-exposed males 
occupied 22% territories and the remaining 31% of the territories were undefended. A 
male was considered a territorial occupant if > 80% of his reads were at a particular 
location. Points represent the number of territories occupied by males from each 
treatment within five populations over a multiday reading frame. Lines represent the best 
fit of the data. Paired observations (one paroxetine point for every control) occur at each 
reader session. When data points from multiple populations overlapped, x-axis scatter 
was created for visual clarity. 
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Figure 3.6. Survivorship of paroxetine-exposed and control animals within the 
OPAs. A) No differences in mortality were detected between treatments in females [n = 
76 (PH; χ 2 = 0.66, p = 0.42)] B) Paroxetine-exposed males (n = 40) experienced a 
marginally significant, twofold increase in mortality rate when compared to controls (PH; 








































3.9 Supplementary Information 
 
 
Figure S3.1. Image of an OPA enclosure. Each enclosure is approximately 30 m2 and is 
divided into six territories by hardware mesh. The four territories containing the large 
blue storage bins are optimal, which are defendable and contain multiple dark nesting 
sites. The suboptimal territories contain light exposed nesting boxes (plantar boxes with 
wire tops). Each territory contains its own water (poultry waterers) and access to food 
(black chimneys). PIT tag antennae (tennis racket like structures) are placed atop the 
feeding stations. Photograph courtesy Doug Cornwall. 
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25% Kcal from added sugar
Cousin inbreeding 
t-complex
Male fitness relative to controls
 
Figure S3.2. Comparison of male reproductive success relative to control 
counterpart from published OPA experiments. Paroxetine exposure had greater 
consequences on male fitness (reproductive success) when compared with cousin 
inbreeding, moderate sugar consumption, and a selfish gene, but suffered less fitness 
consequences when compared to inbreeding at the sibling level (Meagher et al. 2000, 
Carroll et al. 2004, Ilmonen et al. 2008, Ruff et al. 2013). Figure modified from Ruff et 
al. 2013.  
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Table S3.1. Mixed model results for litter size and wean weight between paroxetine-
exposed and control breeders.  
 
 
Litter Size  
 
GLMM with Poisson distribution and logarithmic link 
(groups = 28; observations = 70)  
Random effects Variance Std. Dev.  
Cage (Intercept)  0.0207 0.1441 
Fixed effects Estimate Std. Error z value Pr( > | z | ) 
Intercept (Litter 1)  1.5125 0.0941 16.0760  <0.0001*** 
Treatment (Paroxetine) -0.1128 0.1945  -0.5800   0.5620 
Parity -0.0533 0.0762  -0.6990   0.4850 
Treatment (Paroxetine)×Parity  0.1221 0.1879   0.6500   0.5160 
 
Female Wean Weight  
 








Cage (Intercept)  0.7813 0.8839 
Cage (Slope)  0.2334 0.4831 
Fixed effects  Estimate Std. Error t value Pr( > | t | ) 
Intercept (Litter 1) 10.7732 0.3143 34.2770 <0.0001*** 
Treatment (Paroxetine) -1.9583 0.5286  -3.7050   0.0009*** 
Parity  0.3930 0.2188   1.7960   0.1074 
Treatment (Paroxetine)×Parity  0.1773 0.4137   0.4290   0.6765 
 
Male Wean Weight  
 








Cage (Intercept First Litter)  1.0417 1.0207 
Fixed effects  Estimate Std. Error t value Pr( > | t | ) 
Intercept (Litter 1) 12.3919 0.3750 33.0470 <0.0001*** 
Treatment (Paroxetine)  -2.7664 0.7215  -3.8340   0.0003*** 
Parity   0.2289 0.1713   1.3360   0.1843 
Treatment (Paroxetine)×Parity   0.1867 0.4591   0.4070   0.6852 
*** Indicates a p value <0.001.  
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Table S3.2. Linear mixed model results for body weight over time within OPAs. 
 
Female Body Weight 
 
LMM (groups = 76, observations = 386) 
Random effects Variance  Std. Dev.  
Individual (Intercept) 10.3448 3.2163 
Individual (Slope)   0.0134 0.1157 
Population (Intercept)   5.0655 2.2507 
Population (Slope)   0.0079 0.0887 
Fixed effects  Estimate Std. Error t value Pr( > | t | ) 
Intercept (Week 0) 20.4628 1.2548 16.3070 <0.0001*** 
Treatment (Paroxetine)  -1.0752 1.0308  -1.0430   0.3005 
Time   0.2731 0.0533   5.1200   0.0026** 
Treatment (Paroxetine)×Time  -0.0807 0.0493  -1.6360   0.1064 
 
Male Body Weight 
 
LMM (groups = 40, observations = 179) 
Random effects Variance  Std. Dev.  
Individual (Intercept) 5.6050 2.3675 
Population (Intercept) 3.1113 1.7639 
Population (Slope) 0.0069 0.0831 
Fixed effects  Estimate Std. Error t value Pr( > | t | ) 
Intercept (Week 0) 21.7898 0.9893 22.0250 <0.0001*** 
Treatment (Paroxetine)  -3.3184 0.8415  -3.9430   0.0003*** 
Time   0.1049 0.0404   2.5950   0.0536 
Treatment (Paroxetine)×Time  -0.0050 0.0232  -0.2150   0.8303 
** Indicates a p value < 0.01, *** < 0.001.  
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Table S3.3. Generalized linear mixed model results for reproduction and male 
competitive ability over time within OPAs.  
 
 
Female Reproduction  
 
GLMM with Poisson distribution and logarithmic link  
(groups = 5; observations = 50) 
Random effects Variance Std. Dev.  
Population (Slope)  0.0004 0.0175 
Fixed effects Estimate Std. Error z value Pr( > | z | ) 
Intercept (Week 8)  3.0038 0.0778 38.6300 <0.0001*** 
Treatment (Paroxetine) -0.6350 0.1263 -5.0300 <0.0001*** 
Time -0.0064 0.0102 -0.6300   0.5260 
Treatment (Paroxetine)×Time  0.0384 0.0097  3.9500 <0.0001*** 
 
 
Male Reproduction  
 
GLMM with Poisson distribution and logarithmic link 
(groups = 5; observations = 50) 
Random effects Variance Std. Dev.  
Population (Intercept)  0.0042 0.0650 
Fixed effects Estimate Std. Error z value Pr( > | z | ) 
Intercept (Week 8)  2.1649 0.1171 18.4800 <0.0001*** 
Treatment (Paroxetine) -0.5070 0.1866 -2.7170   0.0066** 
Time  0.0189 0.0087  2.1620   0.0306* 
Treatment (Paroxetine)×Time -0.0074 0.0146 -0.5060   0.6129 
 
 
Male Competitive Ability 
 
GLMM with binomial distribution and logit link (groups 
= 5, observations = 122) 
Random effects Variance Std. Dev.  
Population (Intercept)   0.0168 0.1295 
Fixed effects Estimate Std. Error z value Pr( > | z | ) 
Intercept (Week 3)  -0.1096 0.1908 -0.5750   0.5660 
Treatment (Paroxetine)  -1.1719 0.2850 -4.1130 <0.0001*** 
Time  -0.0017 0.0124 -0.1410   0.8880 
Treatment (Paroxetine)×Time   0.0034 0.0194  0.1760   0.8600 
* Indicates a p value <0.05, ** <0.01, *** <0.001.  
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3.10 Statistical Analyses 
The time taken to produce first litter was analyzed with a Cox proportional hazard 
model (PH). As the gestation period is 21 days, any litters produced on or before day 41 
were considered to be first litters. All breeding pairs that did not produce a litter at this 
time point were censored in the analysis. There were a total of 36 censorings and 24 
events.  
Litter size data are discrete counts and therefore were analyzed with a generalized 
linear mixed model (GLMM) with a Poisson distribution and logarithmic link. The model 
assessed the effects of treatment, parity, and the interaction of parity and treatment. The 
model intercept was set to litter one. Treatment, parity, and their interaction were treated 
as fixed effects while cage was modeled as a random effect with a random intercept 
generated for each. There were 17 paroxetine-exposed litters from eight cages and 53 
control litters from 20 cages used in this analysis.  
Wean weight was analyzed with a linear mixed effects model (LMM). The model 
assessed the effects of treatment, parity, and the interaction of parity and treatment. The 
model intercept was set to litter one. Treatment, parity, and their interaction were treated 
as fixed effects while cage was modeled as a random effect with a random intercept 
generated for each. Sexes were analyzed separately. A normal distribution was assumed, 
as weight data are continuous. Sample sizes used to assess weight differences include: 45 
daughters from eight paroxetine-exposed breeding pairs compared to 89 daughters from 
16 control breeding pairs and 23 sons from eight paroxetine-exposed breeding pairs 
compared to 88 sons from 17 control breeding pairs.  
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Body weight was analyzed with a LMM. The model assessed the effects of 
treatment, time, and the interaction of time and treatment on the 116 population founders. 
Sexes were analyzed separately. A normal distribution was assumed, as weight data are 
continuous. Treatment, time, and their interaction were modeled as fixed effects and 
individual and population were modeled as random effects with random slopes and 
intercepts generated for each. The intercept was set at week zero, as this was when 
founders were released into the enclosures. Collection of founder weight data continued 
on surviving individuals at each pup sweep. There were a total of 386 female 
observations from 76 mice and 179 male observations from 40 mice collected throughout 
the experiment.  
Reproductive outputs were in terms of total offspring and thus are discrete data; 
therefore, these data were analyzed with a GLMM with a Poisson distribution and 
logarithmic link. The model assessed the effects of treatment, time, and the interaction of 
treatment and time on population-level reproduction. These effects were set as fixed 
effects in the model and population was set as a random effect with random intercept 
calculated for each. The intercept was set at week eight, as that was when the first 
collection period or pup sweep occurred. Reproductive output for each treatment was 
measured five times over the course of the 28-week study in each of the five independent 
populations for a total of 50 observations. Female reproductive output was analyzed in 
terms of total offspring and male reproductive success was analyzed in terms of male 
offspring. A post-hoc two-tailed Mann-Whitney U test was used to assess differences at 
each time point for female reproductive success as treatment was found to significantly, 
and oppositely, affect the intercept and slope of the model.  
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 To assess the probability of territorial ownership, a GLMM was used. As a 
territory can be defended or not, a binomial distribution was used with a logit link. There 
were six territories within an enclosure and were either occupied by paroxetine-exposed 
males, control males or unoccupied. A total of 122 observations were collected from five 
populations and analyzed throughout the study. The model assessed the effect of 
treatment, time, and their interaction. These effects were set as fixed effects and 
population was set as a random effect with a random intercept generated for each. The 
model intercept was set to week three, as that was the first time point in which data 
existed in all five populations.  
A multivariate PH was used to assess survivorship of founding individuals. 
Effects of treatment, population, and their interaction were examined in the model. 
Individuals that survived the length of the study or that were intentionally removed from 
the study were censored. Survival in females was assessed in 76 individuals: 14 events 
and 62 censorings. Survival in males was assessed in 40 individuals: 12 events and 28 
censorings.  
Proportional hazard models were conducted in JMP 9.0.3 (SAS institute Inc., 
Cary, NC) and two-tailed Mann-Whitney U tests were performed in Prism 5.03 
(GraphPad Software Inc., La Jolla, CA). All mixed models were conducted in R 3.0.2 
using either glmer or lmer functions within the lme4 library (Bates et al. 2014, R 
Development Core Team 2013). P values were calculated for LMM with the 
Swatterthwaite approximation under the lmerTest function (Kuznetsova et al. 2013).  For 
all mixed models, several candidate models were fit to the data. These models varied in 
terms of random effects that estimated both intercept and/or slope. For each analysis, the 
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model that explained some of the variance with random effects and had the lowest 
Akaike Information Criterion (AIC) score was reported. The significance of treatment or 
the magnitude of the significance varied between models.  
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FACULTATIVE SEX RATIO ADJUSTMENT INCREASES  
FITNESS IN WILD MICE (MUS MUSCULUS) LIVING  
UNDER SEMINATURAL CONDITIONS 
 
4.1 Abstract 
Sex allocation theory suggests that parents who facultatively adjust their sex ratio 
towards the sex that is more likely to have high fitness (Trivers-Willard hypothesis) 
and/or towards the sex that is less energetically demanding to produce (cost of 
reproduction hypothesis) can increase their lifetime reproductive success. We 
investigated the expectations of both the Trivers-Willard hypothesis and the cost of 
reproduction hypothesis in mice whose sex ratios were biased towards females by 
exposure to the pharmaceutical paroxetine. Male offspring born to control dams weighed 
significantly greater than female offspring; however, no differences in wean weights were 
detected between male and female offspring from paroxetine-exposed dams. These data 
suggested that mothers did not save energy by skewing their litters towards females and 
does not support the cost of reproduction hypothesis. Offspring of paroxetine-exposed 
and control dams were released into seminatural enclosure where fitness of all individuals 
was determined. We found that female offspring from treatment dams had significantly 
higher reproductive success compared to the male offspring from the same litters relative 
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to controls. These data suggest that paroxetine-exposed dams were successful at 
increasing their lifetime reproductive success by facultatively adjusting litters towards 
female offspring and it is the first experimental evidence of determining the reproductive 
success of progeny from biased litters that supports the Trivers-Willard hypothesis.  
 
4.2 Introduction  
Perhaps one of the most influential hypotheses in sex ratio theory is the Trivers-
Willard hypothesis (TWH). In polygynous species, a male of high quality can have 
substantial increases in reproductive success by mating with several females while low 
quality males may not breed at all. In contrast, reproductive success differences are not 
nearly as extreme in females, where both low and high-quality females typically produce 
similar numbers of offspring. Trivers and Willard (1973) suggest that high-quality 
mothers produce high-quality sons, who will out reproduce their sisters of the same 
condition; low-quality mothers produce low-quality daughters, who will out reproduce 
their brothers of the same condition. If parents are capable of facultative sex ratio 
adjustment of their offspring in response to environmental conditions, then parents will 
increase their lifetime reproductive success by increasing the rate at which their genes are 
passed onto future generations (Trivers and Willard 1973).  
If differential investment occurs between female and male offspring, then parents 
can skew their litters in favor of the less expensive sex to reduce the cost of reproduction 
and increase their own rates of survival and lifetime fitness, especially when resources 
are limited; this idea is known as the cost of reproduction hypothesis (CRH) (Cockburn et 
al. 2002). The idea of CRH is similar to that of the TWH in that sex ratio adjustment can 
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lessen the risk of reproductive failure and will act to increase lifetime fitness. In terms of 
CRH, low quality mothers are reluctant to invest resources into the sex with the highest 
energy demands (often males in mammals). By preferentially investing into female 
offspring, the mother minimizes her own costs of reproductive efforts. When studying 
sex allocation it can often be difficult to disentangle these hypotheses as often times, 
there is supporting evidence for both hypotheses (Cockburn et al. 2002).  
Experimental manipulations of diets to mimic poor ecological conditions have 
been successful in causing a bias in sex ratio and/or inducing differential investment into 
one offspring sex over the other in several rodent species. For example, when hamster 
dams were calorie restricted during pregnancy and lactation, litters were skewed towards 
female offspring and females weighed more than the male offspring (Labov et al. 1986). 
Likewise, when woodrat dams were calorie restricted during lactation, dams invested 
more into their female offspring than males as measured by offspring weight (McClure 
1981). Mice consuming a low-calorie diet (Meikle and Drickamer 1986) or low-fat diet 
(Rivers and Crawford 1974, Rosenfeld and Roberts 2004) led to female biased litters. 
Although these studies provide evidence for CRH and TWH, these studies do not 
examine the fitness of the offspring from these biased litters to determine if mothers gain 
reproductive benefits by skewing the sex ratio.  
The classic ecological example of TWH is the case of the red deer (Cervus 
elaphus), where dominant females are more likely to produce male offspring than 
subordinate females, as sons produced by dominant females have higher fitness than do 
their daughters (Clutton-Brock et al. 1984, 1986). Interestingly, more recent work on this 
population has revealed that as population densities increase, the biasing of sex ratios 
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towards sons in dominant females has disappeared due to the increased difficulty in 
raising offspring under these conditions. This result, paired with the observation that male 
offspring are more likely to die under low resource conditions (i.e., they are more 
energetically expensive to successfully rear), indicates that the CRH is also at play in 
explaining the sex ratios of this population (Kruuk et al. 1999). In fact, due to the 
countervailing CRH and TWH pressures on sex ratio it has been argued that the original 
observation of bias would not have been made if the original study started in the1990s 
(Cockburn et al. 2002).  
In a previous experiment, we assessed the safety of the antidepressant paroxetine 
[Paxil®, GlaxoSmithKline (GSK), Brentford, England] in wild-derived house mice (Mus 
musculus). We exposed mice to ~1.82 mg/kg/d of paroxetine starting in utero and ending 
in early adulthood. These animals were removed from the treatment and then released 
into seminatural enclosures where they competed against control animals for mates, 
resources, and territories over a 28-week period. We reported that within these 
enclosures, paroxetine-exposed males weighed 13% less, dominated 53% fewer 
territories, and had 44% less offspring relative to controls; likewise, paroxetine-exposed 
females had an initial decline in reproduction relative to controls but rebounded at later 
time points (Chapter 3). We refer to this seminatural mouse model system as organismal 
performance assays (OPAs) and have used to quantify fitness costs of several genetic, 
nutritional, and pharmacological treatments (Meagher et al. 2000, Carroll et al. 2004, 
Ilmonen et al. 2008, Ruff et al. 2013, Ruff et al. in review, Chapter 2, Chapter 3, Chapter 
5). 
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Here we analyze the data from the above study in the context of both the TWH 
and CRH. All comparisons within this paper are unique from those occurring in Chapter 
3. First, we assess whether paroxetine-exposure (from here on referred to as treatment) 
causes biases in the sex ratio of litters relative to theoretical values and control litters. 
Second, we determine if treatment affects litter size. Third, we test if there is differential 
investment in female and male offspring, measured by offspring wean mass, and if the 
degree of this differential investment differs between treatment and control dams. Fourth, 
we determine if female and male offspring of treatment dams have differential lifetime 
fitness (reproductive success) in seminatural enclosures relative to controls. Finally, we 
aim to calculate the fitness benefits achieved through facultative sex ratio adjustment 
when sex ratio skew is detected.   
 
4.3 Materials and Methods 
4.3.1 Animals. Wild-derived genetically outbred house mice were used in this 
experiment as they exhibit natural behavioral characteristics that allow them to function 
in natural and seminatural environments, unlike inbreed mouse strains (Nelson et al. 
2013). In this experiment, animals were from the 12th generation of the colony that is 
described by (Meagher et al. 2000). Genetic diversity was assessed in the 11th generation 
and found to be comparable to that in the wild (Cunningham et al. 2013). Individuals 
were provided access to food and water ad libitum and maintained on a 12:12 hr 
light:dark cycle. All procedures were approved by the University of Utah IACUC.  
4.3.2 Treatment. Paroxetine (GlaxoSmithKline, US, Molecular formula: 
C19H20FNO3?HCl) was administered via diet at a dose of ~1.82 mg/kg/d and has been 
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extensively described in Chapter 3. Sixty breeder pairs were selected for this experiment, 
20 treatment and 40 controls. The asymmetry in cage numbers is because control animals 
were used for both this and another experiment. When paired, female breeders were 75.8 
± 13.2 (M ± SD) weeks old and male breeders were 70.4 ± 13.8 weeks old. All animals 
were individually housed and females were fed their respective diets eight days prior and 
males five days prior to breeding. Breeders were remained together until a maximum of 
four litters were produced. At 28 days of age, litters were weaned and housed with same 
sex siblings. Upon weaning, we recorded individual mass, litter size and sex. After 
weaning, treatment continued until animals were released into the seminatural enclosures, 
at which all animals were provided with the control diet ad libitum.  
4.3.3 Seminatural enclosures. Enclosures have previously been described in (Ruff 
et al. 2013). Briefly, enclosures are ~30 m2 and contained four defendable optimal 
territories with multiple dark nesting sites and direct access to food. In addition, each 
enclosure consisted of two suboptimal territories with nesting boxes exposed to light and 
had indirect access to food. Territories were separated by hardware mesh that was easily 
climbed but added an element of spatial complexity. Food and water were provided ad 
libitum in all territories. Animals were kept on a 12:12 hr light:dark cycle.  
Five independent populations were established and maintained for 28 weeks. 
Populations consisted of eight males and between 14-16 females; these animals are 
referred to as founders for a total of 116 animals. Half of each sex were treatment 
individuals and the remainders were controls. This population structure allows treatment 
individuals to directly compete with controls for resources, territories, and mates. 
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Enclosure space and population size created a population density reported within the 
range observed in the wild (Sage 1981).  
Upon enclosure release, male mice were on average 14.3 ± 4.7 (M ± SD) weeks 
old and females were 18.9 ± 6.9 weeks old. Males were released into enclosure with non-
experimental females to allow males to establish territories and prevent incidental 
breeding with experimental females. Nonexperimental females were removed and 
replaced with experimental females one week later. Although unrelatedness at the cousin 
level or above was ideal for founders, four populations consisted of one to two brother 
pairs and all populations consisted of sister pairs and four populations consisted of sister 
triplets. At most, one male, per treatment or control group, was in a population containing 
two of his sisters. When relatedness was present, it was balanced between treatment and 
control groups.  
4.3.4 Reproductive success within seminatural enclosures. Reproductive success 
of founders was determined by removing and genotyping all offspring during five-week 
intervals within seminatural enclosures and have been described in Chapter 3. Briefly, 
reproductive success was determined on a population-level by examining sex-specific 
allelic variants (Y-chromosome and mitochondrial genome) in three of the five 
populations while the remaining two populations were assessed on an individual level by 
examining multiple autosomal microsatellite loci. Data generated from the multiple 
satellite analysis were converted to population-level readouts (total number of offspring 
per treatment or control groups within a population versus total number of offspring per 
founder). A total of 872 samples were collected with an average of 174.4 ± 38.1 (M ± 
SD) offspring per population. Mitochondrial genotypes were assessed in 626 samples 
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(three of five populations) and obtained for 100% of offspring. Y-chromosome genotypes 
were assessed in all five populations to determine reproductive output and the sex ratio of 
offspring. Of the 872 offspring, 414 Y- chromosome genotypes were obtained, 
suggesting that 95% of all males were typed assuming the sex ratio was 1:1. For the two 
populations that underwent parentage analysis, mother-father-offspring relationships 
were accepted when 95% trio confidence was obtained in Cervus 3.0 (Kalinowski et al. 
2007). Using this rule, 91% (187/205) of one population was genotyped and 75% 
(147/195) of the second population was genotyped.  
 
4.4 Statistical Analyses  
As offspring can only be female or male, sex ratio was analyzed with a 
generalized linear mixed model (GLMM) with a binomial distribution and logit link as is 
recommended (Wilson and Hardy 2002). Birth cage was set as a random effect to control 
for repeated measures as multiple litters (up to four for each breeding pair) were assessed. 
Several candidate models were generated including or excluding litter parity and its 
potential interaction; the final model was selected based the lowest upon AIC score. 
There were 70 observations (litters) from 28 groups (cages).  
As reproduction data are discrete counts, we modeled offspring counts across 
treatment and control breeding cages in a GLMM with a Poisson distribution and a 
logarithmic link. The model assessed the main effects of treatment and litter parity and 
their interaction on litter size. There were 70 observations (litters) made in 28 groups 
(breeding cages). Treatment, litter parity, and their interaction were modeled as fixed 
effects and breeding cage was modeled as a random effect. Several candidate models 
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were generated, including or excluding parity and its potential interaction; the final model 
was selected upon the lowest AIC score. 
For mass comparisons, a linear mixed-effects model (LMM) was used to assess 
the main effects of treatment, sex, and litter parity, as well as their respective interactions 
on the weaning mass of 245 observations (pups) from 25 groups (breeding cages). 
Treatment, sex, litter parity, and their interactions were modeled as fixed effects and 
breeding cage was modeled as a random effect to control for repeated measures as 
multiple litters (up to four) were assessed. Several candidate models were generated 
treating including or excluding parity and its potential interactions; the final model was 
selected based upon the lowest AIC score. 
As offspring can only be female or male, sex ratio was analyzed with a GLMM 
with a binomial distribution and logit link. Reproductive output for each treatment was 
measured five times over the course of the 28-week study in each of the five independent 
populations for a total of 50 observations. Population was set as a random effect to 
control for repeated measures and treatment, time, and their interaction were modeled as 
fixed effects. Several candidate models were generated, including or excluding time. The 
final model was selected based on the lowest AIC score. 
A GLMM with a binomial distribution and logit link was used to determine the 
likelihood of a given offspring born within seminatural enclosures as being produced by a 
female or male offspring from a treatment dam relative to being produced by a female or 
male offspring from a control dam. This method of analysis was selected as raw 
reproduction in enclosures is based on separate measurement for each sex—
mitochondrial and multiple autosomal microsatellite loci for females and Y-chromosome 
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marker for males. By comparing the relative success of treatment female and males 
relative to their control counterparts, comparisons between the relative fitness of 
treatment females and males can be made. Sex, time, and their interaction were modeled 
as fixed effects and population was modeled as a random effect to account for repeated 
measures. Reproductive output was measured five times over the course of the 28-week 
study in each of the five independent populations for a total of 50 observations. Several 
candidate models were generated, including or excluding time, and the final model was 
selected based on the lowest AIC score. 
All GLMMs and LMMs were conducted in R 3.0.2 using the lme4 library (R 
Development Core Team 2013, Bates et al. 2014). Degrees of freedom and resulting p-
values for LMMs were determined with a Satterthwaite approximation using the lmerTest 
library (Kuznetsova et al. 2013). As controversy exists in how to best calculate degrees of 
freedom in LMMs, it should be noted that all effects deemed statistically significant 
through their resulting p-values also possess a t-value > |2|, a conservative criteria for 




Sex ratio was affected by treatment as paroxetine-exposed breeders produced 
litters with a sex ratio of 32:68 M:F, while control breeders had a sex ratio of 51:49 M:F. 
Sex ratio of treatment breeders was skewed towards female offspring when compared 
with an expected 50:50 ratio (GLMM; z = −2.76, p < 0.01; Figure 4.1A) and when 
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compared to control breeders (GLMM; z = 2.39, p < 0.05). For a complete readout of 
mixed model results for breeding cage sex ratio, litter size, and wean mass, see Table 4.1. 
Although significant bias towards male offspring was detected in the treatment 
group, no differences in litter size were observed between treatment and control breeders 
(GLMM; z = 0.18, p = 0.86; Figure 4.1B). Treatment breeders had an average of 4.15 
(SEM + 0.62, −0.53) pups per litter while control breeders had an average of 4.28 (+ 
0.46, −0.63) pups per litter. SEMs are asymmetric, as values have been back-transformed 
from logarithmic data. 
Treatment offspring had reduced mass at weaning than their control counterparts 
(LMM; t = −3.40, p < 0.001; Figure 4.2). In terms of wean mass, control dams invested 
more into their male offspring than their female offspring as male offspring from control 
dams had a mass that was 12.5% (1.54 ± 0.19 g) greater than female offspring at weaning 
(LMM; t = 7.98, p  < 0.0001). Differential investment between male and female offspring 
by treatment dams was reduced relative to controls (LMM; t = −2.68, p < 0.01) as male 
offspring only had a mass that was 4% (0.52 ± 0.38 g) greater that female offspring. 
Litter parity affected wean mass where individuals from subsequent litters were on 
average 0.50 ± 0.16 g heavier (LMM; t = 3.23, p < 0.01). As a significant effect of 
treatment, sex, and their interaction was detected in the LMM, a post-hoc Tukey’s test 
was performed on all pair-wise combinations and all were found to be significant (p < 
0.05), except between the masses of female and male offspring from treatment cages (p = 
0.82), indicating that treatment dams invest equally in regards to the sex of their 
offspring. 
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  In seminatural enclosures, treatment and control founders had an overall sex ratio 
of 44:56 M:F. Sex ratio of treatment founders was skewed towards female offspring 
(GLMM; z = −2.53, p < 0.05) when compared with an expected 50:50 ratio. However, 
they did not differ from those of control founders (GLMM; z = 0.19, p = 0.85), 
suggesting that the overall sex ratio within the seminatural enclosures was biased towards 
females, but did not differ between groups. For a complete readout of GLMM results for 
sex ratio and overall reproductive success comparisons in seminatural enclosures, see 
Table 4.2. 
Female and male treatment founders had reduced reproductive success when 
compared with their control counterparts. The probability that a pup was born to a 
treatment female founder was significantly higher than that of a pup that was sired by a 
treatment male founder (GLMM; z = −2.98, p < 0.001; Figure 4.3), relative to control 
founders. These data suggest that treatment male founders suffered reduced reproductive 
success when compared to their female counterparts, relative to control founders. 
 
4.6 Discussion 
Treatment with paroxetine caused substantial sex ratio skewing relative to both 
symmetric theoretical expectations and control breeding cages. Sex ratios within 
treatment litters were ~1:2 M:F and only one litter out of 17 had a sex ratio of greater 
than 50% male. Sex-ratio biases were not detected in other rodent studies assessing the 
safety and bioactivity of paroxetine possibly due to the use of laboratory mouse strains 
(Coleman et al. 1999), which have undergone generations of selection for consistent and 
reliable reproduction in cages. As this study used wild-derived mice that have been bred 
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to maintain genetic diversity, it is possible that they still possess the, as of yet identified, 
molecular machinery necessary to skew the sex ratio of litters based on the stimulus of an 
external factor such as paroxetine. It has yet to be determined if paroxetine exposure 
consistently skews sex ratios of mice across factors such as age, dose, length of exposure, 
and maternal body weight, but importantly, in the case outlined in this study, it resulted in 
dramatic sex ratio biases. Interestingly, no differences in sex ratios were detected 
between treatment and control founders in seminatural enclosures though both groups 
had significantly fewer males than expected values. The female bias detected in OPAs 
may be due to the stressful seminatural environment but is more likely an artifact as our 
genotyping system is biased to undercounting male offspring. 
Sex ratio was significantly affected by the exposure of paroxetine while no 
differences in litter size was detected when compared to control litters. Although 
mechanisms were not evaluated in this study, Rosenfeld and Roberts (2004) propose four 
nonmutually exclusive theoretical hypotheses to explain mechanisms of sex ratio skewing 
in mammals. Prior to conception, two hypotheses for sex ratio bias are 1) differential 
sperm motility of one class of sperm over the other and 2) one class of sperm may be 
more effective at fertilizing the egg over the other. These two hypotheses are suggested to 
be female mediated as conditions in the reproductive tract can drive this selection. It is 
possible that paroxetine exposures altered the conditions of the female reproductive tract 
that favored X-bearing sperm over Y-bearing sperm. The remaining two hypotheses 
pertain to sex ratio biasing after fertilization has occurred. Hypothesis 3 suggests a 
difference in the rate at which XX and XY embryos develop prior to implantation. In 
litter bearing mammals, faster developing embryos have a competitive advantage when it 
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comes to securing a place of attachment to the uterine wall. As male mice have a higher 
development rate (Valdivia et al. 1993), this hypothesis is unlikely to be supported in our 
study. Hypothesis 4 suggests an increased arrested development in one embryo sex over 
the other. Perhaps males were selectively aborted because they have a faster development 
rate and paroxetine–exposed dams were incapable of sustaining the energetic demands of 
producing male offspring; however, this selective abortion may lead to a reduced litter 
size, which was not detected in our study. Though our findings offer support for some of 
these hypotheses concerning the mechanistic cause of sex ratio adjustment, further 
studies are needed to elucidate the mechanisms of paroxetine-mediated sex ratio bias. 
Though male mice typically have greater masses than their female littermates 
(Chapter 2, Chapter 5), this was not the case for offspring within treatment litters. This 
finding indicates that the CRH does not explain the observed sex ratio biasing, as the 
overproduction of female offspring did not result in an energetic savings for treatment 
dams. The decreased mass of treatment offspring in general relative to controls is an 
indication that treatment dams were in less than optimal condition and unable to invest 
maximally in their litters and therefore, the observed weight data support the first 
requirement of the TWH by indicating that treatment dams are of low quality. As a 
caveat, it should be mentioned that wean mass is a rather gross measure of maternal 
investment, especially as offspring typically begin consuming solid food around day 17, 
although nursing has been documented up until day 28 (Konig and Markl 1987), which is 
when these animals were weaned. However, so long as there is a correlation between 
maternal investment and wean mass, then these data should at least, in part, address the 
question of maternal investment as a function of sex ratio. 
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In seminatural enclosures, treatment founders competed directly with control 
founders and though treatment founders of both sexes performed more poorly than their 
control counterparts this difference was more pronounced in males, lending support to the 
TWH as an explanation for the observed sex ratio biasing. Female treatment founders 
only had 19% fewer offspring while male treatment founders had 44% fewer offspring 
than control founders, which lead to a situation where offspring produced in seminatural 
enclosures were much more likely to be born to female treatment founders than to male 
treatment founders. The differential fitness between male and female treatment founders 
is likely due to the high levels of male intrasexual competition within polygynous mating 
systems, found within house mice societies. Within semi-enclosures, it has been 
demonstrated that territorial dominant males sire ~80% of offspring within an enclosure 
and that treatments that decrease relative rates of territorial acquisition also decrease 
fitness (Meagher et al. 2000, Carroll et al. 2004, Ilmonen et al. 2008, Ruff et al. 2013, 
Chapter 2, Chapter 3). As male treatment founders acquired only half as many territories 
as controls, it is likely that this discrepancy in competitive ability explains the fitness 
differences observed between treatment and control male groups and underscores the 
relative fitness of treatment-born females versus males (Chapter 3). These observations 
support the TWH as an explanation for the observed sex ratio bias as low-quality 
(treatment) mothers produced low-quality sons, who were out reproduced by their sisters 
of the same condition.  
Taken together, the presence of substantial skew in sex ratio towards female 
offspring in treatment breeding cages, and the observation that these females had higher 
fitness than males from the same litters, provides an example of adaptive facultative sex 
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ratio bias in mice. By measuring the fitness of both female and male treatment founders 
relative to controls in seminatural enclosures, we can envision that if a treatment dam 
only had female offspring, then her fitness would be ~81% that of control female and that 
if she only had male offspring, her relative fitness would be ~56%. With these extreme 
cases described, a prediction can be made estimating the second-generation fitness of 
treatment dams relative to controls across varying litter sex ratios (Figure 4.5). It can be 
extrapolated that at the ~1:2 M:F sex ratio observed in treatment litters, dams increased 
their second generational fitness by ~ 5.4% than they would have had with litters 
consisting of a 1:1 sex ratio. Litters containing 0% males would have led to an increase in 
second-generational fitness to 81% and these dams would have reclaimed the maximum 
possible amount of fitness (100%). Litters containing 100% male offspring would have 
lead to a decreased in second-generational fitness to 56% and these dams would have lost 
the most fitness (−100%). Treatment breeders were successful at reclaiming ~ 47% of the 
maximum fitness that could have been obtained by skewing their ratios away from 1:1 
towards ~1:2 M:F. 
Here we have demonstrated that a pharmaceutical agent can dramatically bias sex 
ratios in wild-derived mice and that this facultative biasing is adaptive. Furthermore, by 
assessing maternal investment through wean mass measures and offspring fitness, we 
have determined that TWH and not the CRH best explains our observations as biasing 
does not result in energetic savings to dams, but does result in increased second-
generational fitness. This is also the first experimental evidence determining second-
generational fitness that supports TWH. Though facultative sex ratio biasing is common 
across animal taxa, experimental demonstrations within mammals have proven elusive; 
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our seminatural model system provides an ecologically relevant fitness assay for a well-
studied mammal that could be applied across a battery of treatments documented to 
induce sex ratio biasing to determine their adaptive nature. Furthermore, the 
demonstration that paroxetine exposure induces sex ratio biasing towards female mice 
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Figure 4.1. Sex ratio of litters and litter size from treatment and control breeding 
cages. A) Litters from treatment breeders were female biased and significantly deviated 
from the expected 1:1 sex ratio, [n = 28 cages, observations = 70 litters (GLMM; z = 
−2.78, p < 0.01)]. Likewise, the sex ratio of treatment litters differed significantly from 
that of controls [n = 28 cages, observations = 70 litters (GLMM, z = 2.39, p < 0.05)]. B) 
No differences in litter size were detected between treatment and control breeders [n = 28 
cages, observations = 70 litters (GLMM; z = 0.18, p = 0.86)]. Lines represent means and 










































Table 4.1. Mixed model results for breeding cage litter size, sex ratio, and wean mass. 
 
Sex ratio of litters born in cages 
GLMM with binomial distribution and logit link 
(groups = 28, observations = 70) 
Random effects Variance Std. Dev.  
Cage (Intercept) 0.0463 0.2151 
Fixed Effects Estimate Std. Error z value Pr( > | z | ) 
Treatment (Intercept) -0.7426 0.2670 -2.7810 0.0054** 





GLMM with binomial distribution and logit link 
(groups = 28, observations = 70) 
Random effects Variance Std. Dev.  
Cage (Intercept) 0.0344 0.1856 
Fixed Effects Estimate Std. Error z value Pr( > | z | ) 
Treatment (Intercept) 1.4247 0.1380 10.3240 <0.0001*** 
Control 0.0284 0.1597   0.1780   0.8590 
 
Wean mass of treatment and 
control offspring by sex 
 
 
LMM (groups = 25, observations = 245) 
Random effects  Variance Std. Dev.  
Cage (Intercept) 2.0225 1.4221 
Cage (Slope) 0.2195 0.4686 
Litter Size (Intercept) 0.3360 0.5797 
Fixed Effects Estimate Std. Error t value Pr( > | t | ) 
Intercept (Control) 10.0390 0.4799 20.9180 <0.0001*** 
Treatment -1.5356 0.4521  -3.3960   0.0023** 
Sex (Male)  1.5376 0.1928   7.9770  <0.0001*** 
Sex (Male)*Treatment  1.0165 0.3795  -2.6780   0.0080** 
Parity  0.5026 0.1558   3.2270   0.0066** 















Figure 4.2 Maternal investment in treatment and control offspring as measured by 
wean mass. Treatment pups of both sexes had reduced wean mass when compared with 
their control counterparts [n = 25 cages, observations = 245 offspring (Tukey’s post-hoc 
test; female, p < 0.001; male, p < 0.001)]. In control cages, male offspring had a mass of 
1.54 g greater than female offspring (p < 0.001). However, in treatment cages, male and 
female offspring did not have different masses (p = 0.82). Lines represent means and 


























Table 4.2. Generalized linear mixed model results for sex ratio and overall reproductive 
success comparisons within seminatural enclosures.  
 
 




GLMM with binomial distribution and logit link 
(groups = 5, observations = 50) 
Random effects Variance Std. Dev.  
Population (Intercept) 0.0000 0.0000 
Fixed Effects Estimate Std. Error z value Pr(> | z | ) 
Treatment (Intercept) -0.2592 0.1024 -2.5310 0.0114* 
Control  0.0267 0.1373  0.1950 0.8457 
 
Reproductive output comparisons 
of female and male treatment 
founders relative to controls 
 
 
GLMM with binomial distribution and logit link 
(groups = 5, observations = 50) 
Random effects Variance Std. Dev.  
Population (Intercept) 0.1838 0.4287 
Fixed Effects Estimate Std. Error z value Pr(> | z | ) 
Female Founders -0.2109 0.2042 -1.0330 0.3017 
Male Founders -0.3742 0.1256 -2.9800 0.0029** 





















Figure 4.3. Fitness of female and male treatment founders relative to controls. The 
probability that a pup was born to a female treatment founder was significantly higher 
than the probability of a pup being sired by a male treatment founder [n = 5 populations, 
observations = 50 (GLMM; z = −2.98, p < 0.01)]. The dashed line indicates the level of 
fitness required to be equivalent to controls. Error bars represent standard error from five 
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Figure 4.4. Influence of litter sex ratio on second-generation fitness of treatment 
breeders relative to controls (left y-axis) and the percentage of possible fitness 
recovered by facultative sex ratio adjustment (right y-axis). Within seminatural 
enclosures, total offspring of treatment breeders had 67% of the fitness of control 
breeders (dashed line); however, as the fitness of male offspring to female offspring from 
treatment cages significantly differed, treatment dams would have increased their relative 
fitness to achieve ~81% if they had produced litters with 0% males (top dotted line). On 
the contrary, treatment dams would have decreased their relative fitness to 56% if they 
produced litters with 100% males (bottom dotted line). These extremes are indicated by 
the top and bottom dotted lines and inform the 100% levels of the right y-axis. If 
treatment breeders did not skew their sex ratio and had litters consisted of a 1:1 sex ratio, 
then their second-generation fitness would have decreased by ~5.4%, depicted by the 
closed circle and middle dotted line. The empty square represents the expected fitness 
achieved by treatment breeders at the observed sex ratios. At the level of sex ratio bias 
detected treatment breeders, they were capable of reclaiming ~ 47% of their potential 









ORANISMAL PERFORMANCE ASSAY REVEALS  
INCREASED FEMALE REPRODUCTION WHEN  
EXPOSED TO ROFECOXIB  
 
5.1 Abstract 
We utilized a novel toxicity quantification method known as the organismal 
performance assay (OPA) to assess the safety of rofecoxib, a drug withdrawn from the 
market after being linked with causing more than 27,000 cardiac events. OPAs utilize 
genetically diverse wild mice (Mus musculus) that compete amongst each other for 
limited resources in seminatural enclosures. Performance measures included reproductive 
success, survivorship, and male competitive ability. Within OPAs, rofecoxib-exposed 
males did not suffer performance declines when compared with controls and had equal 
reproduction, competitive ability, and survivorship. Rofecoxib-exposed females 
experienced a 40% higher reproductive output compared to control females. The adverse 
health effects of rofecoxib seen in humans escaped the detection of OPAs and may have 
been because animals in OPAs were no longer on rofecoxib exposure and no cumulative 
damage was caused from previous exposure. This is the second study in which OPAs did 
not detect adversity and therefore, OPAs would still be useful if implemented during 
preclinical studies and other areas of toxicity assessment.  
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5.2 Introduction 
Rofecoxib (Vioxx®, Merck; Whitehouse Station, NJ) is a selective nonsteroidal 
anti-inflammatory drug (NSAID) that was prescribed to patients to relieve arthritic pain. 
The FDA approved rofecoxib in 1999, but it was recalled by Merck in 2004 after the drug 
was shown to increase the risk of cardiovascular events when patients took the drug >18 
months (Keane 2004). During its time on the market, ~107 million prescriptions of 
rofecoxib were dispensed (Krumholz et al. 2007), to 80 million patients (Jüni et al. 2004), 
generating a revenue of $5 billion dollars in sales (Drazen 2005). More than 27,000 
cardiac events were associated with the use of rofecoxib (Horton 2004) and Merck has 
paid more than $6 billion in lawsuit settlements and legal fees (Loftus 2010).  
 Rofecoxib was targeted to reduced prostaglandin synthesis by selectively 
inhibiting cyclo-oxygenase-2 (COX-2) enzymes, which are widely expressed at sites of 
inflammation (Jüni et al. 2004). COX-1 enzymes are expressed in many tissues, including 
gastrointestinal tract (Jüni et al. 2004, Claycomb et al. 2011). Prolonged use of non-
selective NSAIDs, such as naproxen and ibuprofen, can cause gastrointestinal toxicity 
because these drugs inhibit both COX-1 and COX-2 enzymes (Jüni et al. 2004). 
Prostaglandins act as a vasodilator and inhibit platelet aggregation while thromboxane 
(synthesized by COX-1) has the opposite effect, but both are important in maintaining 
cardiovascular homeostasis (Ricciotti and FitzGerald 2011). The imbalance of 
prostaglandins and thromboxane is the suggested mechanism of rofecoxib-induced 
cardiac adversity (Krumholz et al. 2007). 
Preclinical studies were not geared at assessing cardiac safety of rofecoxib. 
Rather, preclinical studies determine if a pharmaceutical of interest causes mutagenicity, 
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carcinogenicity, teratogenicity, and infertility (Merck 2002). Rofecoxib exposure was not 
found mutagenic in rodent cells, nor was it found to be carcinogenic, teratogenic, or 
caused infertility in rodents (Merck 2002). Cardiac adversity was first suspected after 
market release during a phase IV clinical trial Vioxx gastrointestinal outcome research 
(VIGOR) study (Bombardier et al. 2000). These results were later confirmed by the 
adenomatous polyp prevention on Vioxx (APPROVe) study, which ultimately lead to the 
recall of rofecoxib (Keane 2004).    
During human clinical trials, 73% of pharmaceutical that have passed preclinical 
safety assessments fail (Lipsky and Sharp 2001) and 10% of FDA approved 
pharmaceuticals are recalled after market release due to unforeseen toxicity (Schuster et 
al. 2005). The financial costs associated with pharmaceutical development are ~$1.4 
billion per compound and require 12-15 years of research per drug (Miller 2012). 
Pharmaceuticals that fail after FDA approval can cause substantial costs associated with 
litigation fees, such as rofecoxib. One potential solution to reduce human suffering and to 
decrease the high failure rate of approved pharmaceuticals is to employ new 
methodologies in preclinical assessment that provide results without ambiguous 
interpretation.   
We have developed a novel toxicity assay, known as the organismal performance 
assay (OPA), which has the potential to be valuable if implemented during preclinical 
testing. OPAs are comprised of wild mice (Mus musculus) from either a treatment group 
or a control group that compete amongst each other for resources in seminatural 
enclosures. Performance of individuals is measured on an ultimate level in terms of 
Darwinian fitness (i.e., life long reproduction) and its key components (e.g., social 
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dominance and survival). OPAs are capable of revealing mammalian toxicity with high 
sensitivity because this approach challenges most physiological systems synergistically 
and in order for individuals to be successful, high performance from most physiological 
systems is required. OPAs have previously revealed their sensitivity by quantifying the 
effects of cousin and sibling-level inbreeding, harboring a selfish gene, and consuming 
added sugar at human relevant levels (Meagher et al. 2000, Carroll et al. 2004, Ilmonen et 
al. 2008, Ruff et al. 2013), wherein all of these studies, OPAs found substantial 
deleterious effects that were missed by current methodologies.  
Here we use OPAs to determine if rofecoxib exposure causes fitness declines in 
wild mice. Our findings will address the current lack of information concerning rofecoxib 
exposure on ultimate measures (i.e., fitness) of organismal health. If rofecoxib exposure 
adversely affects any physiological system, we predict that exposed individuals will 
suffer survival, dominance, and reproduction declines relative to controls.  
 
5.3 Materials and Methods 
5.3.1 Animals. Genetically diverse, wild-derived house mice (Mus musculus) were 
used in this experiment. Wild mice possess natural behaviors needed to function within 
seminatural environments (Nelson et al. 2013). The wild mice used in this experiment 
were from the 12th generation of the colony described by (Meagher et al. 2000). Genetic 
diversity of this colony was assessed in the 11th generation and found to be comparable to 
wild populations (Cunningham et al. 2013). Animals were provided food and water ad 
libitum and maintained on a 12:12 hr light:dark cycle. All procedures and protocols were 
approved by the University of Utah IACUC.  
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5.3.2 Drug exposure. Dosing was achieved by incorporating 12.5 g of rofecoxib 
(AK Scientific Inc. Union City, CA; Molecular formula: C17H14O4S) into 50 kg of rodent 
chow (TD.130006; Harlan Teklad, Madison, WI). As wild mice eat approximately 3 g 
per day and weigh 20 g (Reagan-Shaw et al. 2008), individuals will ingest 0.75 mg of 
rofecoxib per day or 37.5 mg/kg/day. Using a metabolic rate conversion factor, this is 
equivalent to a human dose of 3.0 mg/kg/day, or a daily dose of 182.4 mg, assuming the 
average human weighs 60 kg (Reagan-Shaw et al. 2008). Rofecoxib was prescribed at 
doses 12.5 – 50 mg/d (Merck 2002), thus animals in this experiment were exposed to a 
dose 3.5 fold higher than human therapeutic dose but it is within the range of doses in 
preclinical studies (Merck 2002).  
Sixty breeding pairs were selected for this experiment and divided into two 
treatments: rofecoxib-exposed or control. All breeders were individual housed eight days 
prior to pairing. Females in the rofecoxib treatment started exposure at this time while 
males in the rofecoxib treatment started exposure five days prior to pairing. Breeding 
pairs were kept together until a maximum of three litters were produced. All offspring 
were weaned at 28 days old and housed with same sex siblings. Upon weaning, litter size, 
sex, and weight were recorded. Offspring were kept on their respective diets until adults 
and released into the OPA enclosures. This duration of rofecoxib exposure maximized 
the ability of OPAs to detect health consequences as once released into the seminatural 
enclosures, all animals were fed the control diet because we are currently unable to keep 
animals on their respective diets while they are free ranging during OPAs. Switching the 
rofecoxib-exposed animals to the control diet was the most conservative approach of 
detecting fitness impacts as cumulative damage of the pharmaceutical prior to OPAs. 
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5.3.3 OPA enclosures. Enclosures have previously been described in (Ruff et al. 
2013). Briefly, there are 11 independent enclosures approximately 30 m2. Each enclosure 
is divided into six territories by hardwire mesh that is easily climbed but adds a 
component of spatial complexity. Optimal territories (n = 4) consisted of a large storage 
bin with multiple dark nesting sites and direct access to food. Suboptimal territories (n = 
2) consisted of light-exposed nesting sites. All territories contained ad libitum access to 
food and water and were kept on a 12:12 hr light:dark cycle. 
Five independent OPA populations were established and four were maintained for 
28 weeks. One population was terminated at 11 weeks due to 100% control male 
mortality and because the enclosure was needed for another experiment. Populations 
consisted of eight to 10 males and 12-18 females for a total of 116 animals (42 male, 74 
female).  Half of each sex were from the rofecoxib-exposed treatment while the 
remaining half served as controls. The population structure allowed for direct competition 
between treatment and control individuals. Enclosure space and population size created a 
population density reported within the range observed in the wild (Sage 1981).  
Upon enclosure release, male mice were on average 16.31 (SD ± 5.24) weeks old 
and females were 15.34 (SD ± 5.31) weeks old. To allow males to establish territories 
and prevent incidental matings, males from both treatments were released into the 
enclosures with nonexperimental females. One week later, nonexperimental females were 
removed and replace with experimental females from both treatments. Unrelated 
individuals at the cousin level or above was ideal for OPA populations. Three populations 
consisted of one set of brothers but no males were related to females. Four populations 
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consisted of one or two sister pairs, four populations consisted of sister triplets, and one 
population consisted of sister quadruplets. Relatedness was balanced between treatments.   
5.3.4 Reproductive success. Founder reproductive success was determined by 
genetically analyzing offspring born in the enclosures. Offspring were first removed at 
week eight, then during five-week intervals, referred to as pup sweeps. This time interval, 
prevented offspring from reaching sexual maturity and from confounding the 
reproductive success data. During pup sweeps, offspring were removed, sacrificed, and a 
tissue sample was collected for genetic analyses. A total of 1,138 samples were collected 
with an average of 227.60 ± 104.50 (M ± S.D.) offspring per population. 
 A population-level approach was used to determine reproductive success in three 
of the five populations described in (Meagher et al. 2000). Briefly, founder individuals 
from each treatment were selected upon nonoverlapping sex-specific allelic variants, 
females upon the mitochondrial genome and males on the Y-chromosome. To control for 
confounding effects, such as segregating genes linked with the markers, reciprocal 
markers were assigned across populations. Mitochondrial genotypes were assessed in 860 
samples (three of five populations) and obtained for 100% of offspring. Of the 1,138 
offspring, 570 Y-chromosome genotypes were obtained (from all five populations), 
suggesting that 100% of all males were typed if the sex ratio was 1:1.  
Reproductive success was determined by multiple microsatellite loci in one 
population. One population was left ungenotyped as the results of this population would 
not have influenced the overall trends of female reproductive success results to meet our 
predictions. Microsatellite data were converted to population levels readouts and 
combined with the mitochondrial and Y-chromosomal data for analysis. Between six and 
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11 autosomal microsatellite loci were amplified, scored, and analyzed in a stepwise 
fashion. Loci used were: d1mit251, d1mit449, d3mit22, d3mit312, d3mit333, d6mit138, 
d9mit232, d9mit251, d12mit277, d14mit128, and d19mit110. Primer sequences were 
obtained from the Mouse Genome Informatics website, The Jackson Laboratory, Bar 
Harbor Maine (http://www.informatics.jax.org/ accessed March 2014). Fluorescently 
tagged primers were used in PCR reactions (CY-5 or CY-3). Tagged PCR products were 
run on 14” x 17”, 6.25% denaturing acrylamide gels at 40 W for three to seven hours 
(locus dependent). Gels were imaged on a Typhoon Scanner 8600 and ImageQuant 
software (Amersham Biosciences, Piscataway, NJ). 
Parentage was assigned by using Cervus 3.0 (Kalinowski et al. 2007), a program 
that uses a likelihood based statistical approach. Allele frequencies were calculated using 
the genotypes of all candidate mothers and fathers and all offspring within the population. 
Simulations were run 10,000 cycles with an error rate of 1% to derive a delta score. 
Assigned parents were accepted when the trio confidence of mother, father, and offspring 
was 95%. With this rule, 86% (49/57) of the population was genotyped.  
5.3.5 Male competitive ability. Prior to OPA release, all individuals received a 
PIT (passive integrated transponder) tag (TX1400ST, BioMark, Boise, ID) and a unique 
ear punch for identification purposes. Two sets of PIT antenna and readers (FS2001F-
ISO, BioMark, Boise, ID) were used in this experiment and were rotated twice per week 
among concurrent populations. PIT tag antennas were placed above each feeding station 
within the six territories of an enclosure. All PIT tag data were downloaded to a computer 
containing data logging software (Minimon, Culver City, CA). A male was considered 
territorial occupant (dominant) in a territory if  > 80% of the total reads belonged to him 
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at a particular location. PIT tag data were collected on female mice; however, they were 
not analyzed due to the lack of information on female dominance behavior. 
5.3.6 Survivorship. Survivorship was assessed by daily noninvasive health checks 
and extensive enclosure checks during pup sweeps. Extensive checks were not performed 
at a higher frequency as to not disrupt territoriality formation, which increases 
infanticidal behavior. Research personnel entered enclosures only to freshen wateres, fill 
feeders, rotate PIT tag readers, remove deceased individuals, and to conduct pup sweeps. 
Deceased founders were identified by PIT tag IDs. The date of death was estimated upon 
the condition of the corpse. Individuals that had died long before research personnel 
discovered it were given a death date half way between the date it was found and the last 
date it was read by PIT tag readers.  
 
5.4 Statistical Analyses. 
Wean weight of offspring was analyzed with a linear mixed-effects model 
(LMM). This model assessed the effects of treatment, time, and the interaction of time 
and treatment. The model intercept was set to litter one. Treatment, parity, and their 
interaction were treated as fixed effects while cage was modeled as a random effect with 
a random intercept generated for each. Sexes were analyzed separately. A normal 
distribution was assumed because weight data are continuous. Sample sizes used to 
assess weight differences include: 21 daughters from seven rofecoxib-exposed breeding 
pairs, 75 daughters from 16 control breeding pairs, and 26 sons from eight rofecoxib-
exposed breeding pairs compared to 71 sons from 17 control breeding pairs.  
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Litter size data are discrete counts and therefore were analyzed with a generalized 
linear mixed model (GLMM) with a Poisson distribution and logarithmic link. This 
model assessed the effects of treatment, time, and the interaction of time and treatment. 
The model intercept was set to litter one. Treatment, parity, and their interaction were 
treated as fixed effects while cage was modeled as a random effect with a random 
intercept generated for each. There were 21 rofecoxib-exposed litters and 44 control 
litters for a total of 65 observations from 30 cages in this analysis. Reported SEMs are 
asymmetric because values have been back-transformed from logarithmic data. 
Body weight was analyzed with a LMM. This model assessed the effects of 
treatment, time, and the interaction of time and treatment on the 116 population founders 
(females = 72, males = 42). Sexes were analyzed separately. A normal distribution was 
assumed because weight data are continuous. Treatment, time, and their interaction were 
modeled as fixed effects and individual and population were modeled as random effects 
with random slopes and intercepts generated for each. The intercept was set at week zero, 
as this was when founders were release into the enclosures and at which collected of 
weight data from OPAs began. Collection of founder weight data continued on surviving 
individuals at each pup sweep. There were a total of 337 female observations and 142 
male observations collected throughout the experiment.  
Reproductive outputs were in terms of total offspring and thus are discrete data. 
These data were analyzed with a GLMM with a Poisson distribution and logarithmic link. 
The model assessed the effects of treatment, time, and the interaction of treatment and 
time on population-level reproduction. These effects were set as fixed effects in the 
model and population was set as a random effect with random intercept calculated for 
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each. The intercept was set at week eight, as that was when the first collection period or 
pup sweep occurred. Male reproductive output for each treatment was measured five 
times over the course of the 28-week study in each of the five independent populations 
(except for one population that was only measured two times) for a total of 44 
observations. Female reproductive output for each treatment was measured five times 
over the course of the 28-week study in four independent populations (except for one 
population that was only measured two times) for a total of 34 observations. Female 
reproductive output was analyzed in terms of total offspring and male reproductive 
success was analyzed in terms of male offspring. Reported SEMs are asymmetric because 
values have been back-transformed from logarithmic data. 
To assess the probability of territorial ownership, a GLMM was used. As a 
territory can be defended or not, a binomial distribution was used with a logit link. There 
were six territories within a population and were either occupied by rofecoxib-exposed 
males, control males, or unoccupied. A total of 104 observations were collected and 
analyzed throughout the study. The model assessed the effect of treatment, time, and their 
interaction. These effects were set as fixed effects and population was set as a random 
effect with a random intercept generated for each. The model intercept was set to week 
three as that was when data existed for each population.  
Survival of founders was analyzed by a multivariate Cox proportional hazard 
model. Impacts of treatment and population were examined in the model. In the male 
analyses, the interaction of treatment and population was also assessed. This was not 
possible for females because of low mortality (n = 2). Sexes were analyzed separately 
due to differences in mortality rates. Individuals that survived the length of the study or 
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that were intentionally removed from the study were censored. A total of 74 females were 
analyzed; two events and 72 censorings; and 42 males were analyzed; 17 events and 25 
censorings.  
Proportion hazard models were conducted in JMP 9.0.3 (SAS institute Inc., Cary 
NC). All mixed models were conducted in R 3.0.2 using either glmer or lmer functions 
within the lme4 library (Bates et al. 2014, R Development Core Team 2013). P values 
were calculated for LMM with the Swatterthwaite approximation under the lmerTest 
function (Kuznetsova et al. 2013). For all mixed models, several candidate models were 
fit to the data. These models varied in terms of random effects that estimated both 
intercept and/or slope. For each analysis, the model that explained some of the variance 
and with the lowest Akaike information criterion (AIC) score was selected and reported. 
Neither the significance of a fixed effects nor the magnitude of the significance varied 
between models.  
 
5.5 Results 
5.5.1 Breeding cage. No difference in wean weight was detected due to rofecoxib 
exposure (LMM; female offspring, t = −0.80, p = 0.42; male offspring, t = −1.28, p = 
0.20). At the model intercept (litter one), rofecoxib-exposed female offspring weighed on 
average of 10.60 g (SEM ± 0.66) while controls weighed an average of 11.13 g (± 0.33). 
No effect of time (LMM; t = −0.45, p = 0.65) or time by treatment (LMM; t = 0.76, p = 
0.45) was detected. Rofecoxib-exposed male offspring weighed on average 11.05 g (± 
0.81) and controls weighed on average 12.09 g (± 0.37). There was a significant increase 
in male weight over time (LMM; t = 2.85, p < 0.01), but this trend was consistent 
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between treatments (LMM; t = 0.04, p = 0.97). For a complete readout of mixed model 
results for breeding cage data, see Table 5.1. 
A trend was detected where rofecoxib-breeders produced smaller litters (GLMM; 
z = −1.70, p = 0.09; Figure 5.1). In first litters (model intercept), rofecoxib-exposed 
breeders produced an average of 3.09 pups (SEM +0.69, −0.57), while control breeders 
produced 4.36 pups (+0.48, −0.43). No effect of time (GLMM; z = 0.30, p = 0.77) or 
time by diet (GLMM; z = 1.08, p = 0.28) was detected, suggesting the trend of reduced 
litter size was consistent over time.  
5.5.2 OPA measurements. Rofecoxib-exposure did not affect female body weight 
at the model intercept (week zero of LMM; t = 0.21, p = 0.83; Figure 5.2A). Rofecoxib-
exposed females weighed on average 19.68 g (SEM ± 1.02) and controls weighed on 
average 19.47 g (± 0.97). Females gained weight over time, due to pregnancy (LMM; t = 
12.02, p < 0.0001), and this effect was consistent between treatments (LMM; t = −0.81, p 
= 0.42). Rofecoxib-exposed males showed a marginally significant trend of reduced 
weight at the model intercept (week zero) when compared with controls (LMM; t = 
−1.78, p = 0.08; Figure 5.2B). Rofecoxib-exposed males weighed on average 20.13 g (± 
0.73) and controls weighed on average 21.43 g (± 0.51). Males from both rofecoxib and 
control treatments gained weight over time (LMM; t = 4.54, p < 0.0001) and a treatment 
by time effect was detected (LMM; t = 1.983, p < 0.05), suggesting that rofecoxib-
exposed males gained weight over time than did controls. For a complete readout of 
mixed model results for OPA weight measures data, see Table 5.2. 
Rofecoxib-exposure increased female reproductive success by 40% relative to 
controls. At model intercept (week eight), rofecoxib-exposed females had significantly 
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more offspring than controls (GLMM; z = 3.89, p < 0.0001; Figure 5.3A) with a mean of 
28.76 offspring per population (SEM +3.44, −3.07). Control females had a mean of 18.53 
offspring per population (+4.24, −3.44). No effect of time (GLMM; z = 0.39, p = 0.70) or 
time by diet interaction (GLMM; z = 1.20, p = 0.23) was detected; suggesting rofecoxib-
exposed females had more offspring throughout the duration of the study. For a complete 
readout of mixed model results for OPA reproduction and competitive ability, see Table 
5.3.  
Rofecoxib exposure did not impact male reproductive success (GLMM; z = 0.19, 
p = 0.85; Figure 5.3B). At model intercept (week eight), rofecoxib males sired on 
averaged 10.31 male offspring (SEM +1.87, −1.41) per population. Control males had an 
average of 10.03 male offspring (+1.96, −1.64) per population. No effect of time was 
detected (GLMM; z = 1.38, p = 0.17). A trend was detected in which rofecoxib-exposed 
males produced fewer male offspring over time (GLMM, z = −0.05, p = 0.09). 
Male competitive ability was not impacted by treatment. At week three (model 
intercept), control males occupied 30% of territories, rofecoxib-exposed males occupied 
30%, leaving 40% of territories unoccupied (GLMM; z = 0.08, p = 0.94; Figure 5.4). The 
percent of undefended territories is not unusual because 2/6 (or 33%) of the territories are 
suboptimal and often difficult to defend. There was a marginally significant increase in 
the number of territories being occupied over time (GLMM; z = 1.72, p = 0.09); but no 
time by diet interaction occurred (GLMM; z = −0.27, p = 0.79), suggesting that males 
from both treatments occupied more territories over time. 
A trend was detected in which control female suffered more mortality (PH; χ2 = 
2.93, p = 0.09; Figure 5.5A). However, this is based upon only two mortalities from 74 
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females. Mortality rate did not differ in replicate populations (PH; χ2 = 6.15, p = 0.19). 
No significant differences were detected in male mortality between treatments (PH; χ2 = 
0.04, p = 0.83; Figure 5.5B). Mortality rate did not differ in replicate populations (PH; χ2 
= 4.85, p = 0.30), nor was there a difference in the effect of treatment among populations 
(PH; χ2 = 2.92, p = 0.57).  
 
5.6 Discussion 
Rofecoxib-exposure did not affect survivorship, weight, male competitive ability, 
or male reproductive success within OPAs. Results from this experiment are conservative 
as rofecoxib exposure ceased when animals were released into enclosures and were all 
fed the control diet. One possible explanation for our observed results is that the drug did 
not cause lasting deleterious effects and after exposure ceased, exposed individuals 
rebound to average fitness. A second explanation is perhaps animals in this experiment 
were not exposed to rofecoxib long enough to induce fitness effects. Animals were 
exposed to rofecoxib during gestation and to ~15-16 weeks of age whereas cardiac 
adversity was not detected in humans until after taking the prescription for >18 months. 
Another possible explanation is that although cardiac events occurred in 27,000 people, 
an estimated 80 million people took the drug (Jüni et al. 2004), suggesting < 0.4% of 
people who took the drug had a cardiac event. Due to such a small percentage of cardiac 
adversity in humans, this effect was likely to go undetected in five populations of mice 
with 116 individuals.    
 Rofecoxib-exposed litters tended to be smaller when born in cages. This result is 
in line with previous research on NSAIDs that have shown these drugs can cause 
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transient infertility (Østensen et al. 2006), as prostaglandin synthesis is important for 
normal ovulation (Sugimoto 1997). Prostaglandin synthesis disruption was also suggested 
to be the cause of increased embryo loss in rofecoxib-exposed rats during preclinical 
studies (Merck 2002).  
Although rofecoxib-exposed litters tended to be smaller in cages, when animals 
were in OPAs, rofecoxib-exposed females had 40% more offspring when compared to 
controls. One factor that may be affecting these results is that there were fewer 
populations than what is typical in OPA assessments. Female reproductive success was 
analyzed in four populations up to week 13 and only in three populations for the 
remaining portion of the study. Regardless of sample size, these contrasting results are 
interesting because the main variable that changed was the type of environment these 
animals were in and because increased reproduction was detected in a treatment where 
the immune system is targeted. Tradeoffs exist between pregnancy and the immune 
system and because rofecoxib suppresses the immune system, perhaps less energy was 
allocated towards immune function and more energy was allocated to pregnancy 
(Sheldon and Verhulst 1996). The fact that we detected a positive impact on female 
reproduction within seminatural environments is curious and warrants further 
investigation.  
 OPA assessment of rofecoxib is the second case in which no adverse health 
consequences were detected. In an unpublished study examining the health consequences 
of a nanomaterial (polyamidoamine dendrimers, PAMAM), no negative effects were 
detected. However, in four published OPA studies and in two pharmaceutical studies, at 
least one OPA endpoint (reproductive success, survivorship, or male competitive ability) 
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was negatively affected in at least one sex of treatment individuals (Figure 5.6) (Meagher 
et al. 2000, Carroll et al. 2004, Ilmonen et al. 2008, Ruff et al. 2013, Chapter 2, Chapter 
3). In all of these studies, OPAs revealed greater fitness consequences than in previous 
experimentation, thus providing support for the sensitivity of OPAs and because OPAs 
did not detect consequences in two substances does not negate the importance of 
implementing OPAs in toxicity assessment.  
Although the detection of negative health consequences induced by rofecoxib 
exposure slipped the detection by OPAs, they were also missed by preclinical trials and 
we believe that OPAs would still be beneficial to be implemented within pharmaceutical 
development. In addition to the proximate-level animal studies, OPAs would be useful 
because they quantify fitness on an ultimate level that provides clear interpretation on 
overall health. This is achieved because of the nature of OPAs that challenge most 
physiological systems synergistically and simultaneously and are useful in revealing 
disease phenotypes that can then undergo further investigation for mechanistic cause. 
OPAs would be a useful tool to implement in pharmaceutical development and other 
areas of toxicity assessment.  
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Table 5.1. Mixed model results for litter size and wean weight from breeding cages. 
 
 
Litter Size  
 
GLMM with Poisson distribution and logarithmic link  
(groups = 30, observations = 65) 
Random effects Variance Std. Dev.   
Cage (Intercept) 0.0173 0.1316   
Fixed effects Estimate Std. Error z value Pr(>|z?) 
Intercept (Litter 1)  1.4721 0.1047 14.0590 <0.0001*** 
Treatment (Rofecoxib) -0.3432 0.2020  -1.6990   0.0894 
Parity  0.0267 0.0903    0.2950   0.7678 
Treatment (Rofecoxib)×Parity  0.2085 0.1929    1.0800   0.2800 
 
Female Wean Weight 
 
LMM (groups = 23, observations = 96) 
Random effects Variance  Std. Dev.   
Cage (Intercept) 0.8188 0.9049   
Fixed effects  Estimate Std. Error t value Pr( >|t?|) 
Intercept (Litter 1) 11.1311 0.3242 34.3330 <0.0001*** 
Treatment (Rofecoxib) -0.5296 0.6608 -0.8010   0.4270 
Parity -0.0937 0.2064 -0.4540   0.6510 
Treatment (Rofecoxib)×Parity  0.3591 0.4697  0.7640   0.4470 
 
Male Wean Weight 
 
LMM (groups = 25, observations = 97)  
Random effects Variance  Std. Dev.   
Cage (Intercept) 1.0400 1.0200   
Fixed effects  Estimate Std. Error t value Pr( >|t?|) 
Intercept (Litter 1) 12.0867 0.3715 32.5300 <0.0001*** 
Treatment (Rofecoxib) -1.0360 0.8101  -1.2800   0.2048 
Parity  0.6496 0.2277   2.8500   0.0054** 
Treatment (Rofecoxib)×Parity  0.0250 0.5889   0.0400   0.9663 









Figure 5.1. Litter size at weaning age from all litters produced by rofecoxib-exposed 
and control breeders. A trend was detected where rofecoxib-exposed breeders produced 
smaller litters [n = 30, observations = 65 (GLMM; z = −1.70, p = 0.09)]. Lines represent 
























Figure 5.2. Body weight of rofecoxib-exposed and control founders within OPAs 
over time. A) No differences in body weight between treatments were detected in 
females at model intercept [n = 74, observations = 337 (week zero of LMM; t = 0.21, p = 
0.83)]. Both rofecoxib-exposed and control female gained weight over time (LMM; t = 
12.02, p < 0.0001). B) A trend was detected where rofecoxib-exposed males weighed less 
than controls at the model intercept [n = 39, observations = 142 (week 0 of LMM; t = 
−1.78, p = 0.08)]. Males gained weight over time (LMM; t = 4.54, p < 0.0001) and 
rofecoxib-exposed males gained more weight over time than controls (LMM: t = 1.98, p 

































Table 5.2. Linear mixed model results for body weight over time within OPAs. 
 
Female Body Weight  
 
LMM (groups = 74, observations = 337) 
Random effects Variance  Std. Dev.   
Individual (Intercept) 9.2891 3.0478   
Population (Intercept) 1.9916 1.4112   
Fixed effects  Estimate Std. Error t value  Pr( >|t?|) 
Intercept (Week 0) 19.4696 0.9668 20.1380 <0.0001*** 
Treatment (Rofecoxib)   0.2144 1.0208   0.2100   0.8340 
Time   0.3916 0.0326 12.0220 <0.0001*** 
Treatment (Rofecoxib)×Time  -0.0357 0.0442  -0.8080   0.4200 
 
Male Body Weight  
 
LMM (groups = 39, observations = 142) 
Random effects Variance  Std. Dev.   
Individual (Intercept) 2.3450 1.5314   
Fixed effects  Estimate Std. Error t value Pr( >|t?|) 
Intercept (Week 0) 21.4308 0.5111 41.9270 <0.0001*** 
Treatment (Rofecoxib) -1.3016 0.7323 -1.7770   0.0793 
Time  0.1116 0.0246  4.5420 <0.0001*** 
Treatment (Rofecoxib)×Time  0.0715 0.0361  1.9830   0.0495* 
* Indicates a p value < 0.05, *** < 0.001. 
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Figure 5.3. Reproductive success of rofecoxib-exposed and control animals in OPAs. 
A) Rofecoxib-exposed females had 40% more offspring than controls [n = 4, 
observations = 34 (GLMM; z = 3.89, p < 0.0001)] and this effect was consistent 
throughout the study. B) No difference in male reproductive success was detected 
between treatments [n =5, observations = 44 (GLMM; z = 0.19, p = 0.85)]. A trend was 
detected in which rofecoxib males had more male offspring over time (GLMM; z = 
−0.05, p = 0.09). Female reproduction is in terms of total offspring as mitochondrial and 
multiple microsatellite markers that were used. Male reproduction is in terms of male 
offspring due to using Y-chromosome markers. Lines connect means of the populations 
at each time point for each sex and error bars represent standard error.  















































Table 5.3. Generalized linear mixed model results for reproduction and male competitive 
ability over time within OPAs.  
 
 
Female Reproduction  
 
GLMM with Poisson distribution and logarithmic link  
(groups = 4, observations = 34) 
Random effects Variance Std. Dev.   
Population (Intercept) 0.1755 0.4189   
Population (Slope) 0.0008 0.0283   
Fixed effects Estimate Std. Error z value Pr( >|z?) 
Intercept (Week 8)  2.8937 0.2283 12.6760 <0.0001*** 
Treatment (Rofecoxib)  0.4393 0.1129  3.8910 <0.0001*** 
Time  0.0063 0.1616  0.3900   0.6960 





GLMM with Poisson distribution and logarithmic link  
(groups = 5, observations = 44) 
Random effects Variance Std. Dev.   
Population (Intercept) 0.1036 0.3219   
Population (Slope) 0.0002 0.0150   
Fixed effects Estimate Std. Error z value Pr( >|z?) 
Intercept (Week 8)  2.3056 0.1786 12.9100 <0.0001*** 
Treatment (Rofecoxib)  0.0273 0.1468   0.1860   0.8530 
Time  0.0156 0.0113   1.3830   0.1670 
Treatment (Rofecoxib)×Time -0.0006 0.0117  -0.0520   0.0959 
 
 
Male Competitive Ability 
 
GLMM with binomial distribution and logit link  
(groups = 5, observations = 104) 
Random effects Variance Std. Dev.   
Population (Intercept week 3) 0.1287 0.3587   
Fixed effects Estimate Std. Error z value Pr( >|z?) 
Intercept (Week 3) -0.8640 0.2525 -3.4220  0.0006*** 
Treatment (Rofecoxib)  0.0208 0.2767  0.0750  0.9401 
Time  0.0272 0.0158  1.7210  0.0853 
Treatment (Rofecoxib)×Time -0.0059 0.0221 -0.2670  0.7895 





































Figure 5.4. Male competitive ability between rofecoxib-exposed males and controls. 
Rofecoxib-exposed males and control males occupied the equal percentages of territories, 
30% each [n = 5, observations = 104 (GLMM; z = 0.08, p = 0.94)]. This effect was 
consistent throughout the study. A male was considered dominant, or a territorial 
occupant, when > 80% of his reads were at a particular location. Points represent the 
number of territories occupied by males from each treatment over a multiday reading 
frame. Lines represent the best fit of the data. Paired observations (one rofecoxib point 
for every control) occur at each reader session. When data points from multiple 









Figure 5.5. Survivorship of rofecoxib-exposed animals compared to controls in 
OPAs. A) A trend was detected where control females suffered higher mortality than 
rofecoxib-exposed females [n = 74 (PH; χ2 = 2.93, p = 0.09)]; however, this is based upon 
two mortalities. B) No differences in male mortality was detected between treatments [n 














































Male fitness relative to controls
 
Figure 5.6. Comparison of male reproductive success relative to control counterpart 
from previous OPA experiments. Rofecoxib did not affect male fitness when compared 
with controls. Rofecoxib males had higher fitness when compared with both cousin level 
and sibling level inbreeding, 25% high fructose corn syrup consumption, a selfish gene, 
and the exposure of cerivastatin and paroxetine (Meagher et al. 2000, Carroll et al. 2004, 
Ilmonen et al. 2008, Ruff et al. 2013, Chapter 2, Chapter 3). 
 
 
 
 
 
 
 
 
